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Systematic review of pharmacogenomics in psoriasis
AC Foulkes,1 A Jorgensen,2 M Pirmohamed,2 CE Griffiths1 and RB Warren1 1 The Dermatology
Centre, University of Manchester, Manchester, United Kingdom and 2 Wolfson Centre for
Personalised Medicine, Liverpool, United Kingdom
Pharmacogenetic and pharmacogenomic studies have investigated biomarkers of drug efficacy and
toxicity in psoriasis, yet none have translated into clinical care. We performed a systematic review
of publications assessing the influence of genetic/genomic variation on treatment response in pso-
riasis patients. Studies were included where: participants had a diagnosis of psoriasis; a genomic
test was performed; response to treatment was documented with a defined outcome measure and
treatment response was correlated with the genomic test. Four electronic databases were searched
from inception to August 2012. In total 27,203 abstracts were scanned, from which 121 full papers
were evaluated; only 45 studies, published between 1995 and 2012, met inclusion criteria. Thera-
pies evaluated included 9 topical, 8 phototherapy, 8 systemic, 19 biologic and 3 novel immunother-
apies. Of the 26 pharmacogenetic and 19 pharmacogenomic studies, only 2 reported undertaking
a sample size calculation before patient recruitment. A positive association with efficacy or toxic-
ity and genetics/genomics was reported by 33 studies. Sources of heterogeneity included: poor
phenotyping of participants; failure to define treatment response using validated methodology; tim-
ing of measurement of response and; documentation of participants’ concurrent therapies. Key qual-
ity control data were rare, including accuracy of genotyping in pharmacogenetic studies (2 of 26)
and derivation of statistically significant fold change in gene expression. To realise the power of
genomics in the field of personalised medicine, genomic screening prior to psoriasis therapy must
be accurate and effective in predicting response and in preventing adverse reactions. Thus we rec-
ommend: high quality phenotyping of participants; publication of reproducible methodology includ-
ing a priori power to detect association; use of a validated outcome measure for measurement of
psoriasis and; a clear definition of response.
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Hospitalizations for cellulitis in Canada: A retrospective database study
A Baibergenova,1,2 A Drucker2 and N Shear2,1 1 Dermatology, Sunnybrook Health Sciences
Centre, Toronto, ON, Canada and 2 Dermatology Division, University of Toronto, Toronto,
ON, Canada
Background: Cellulitis is the most common skin condition responsible for emergency department
visits and inpatient admissions in Canada. This study examined hospitalization records of patients
admitted for cellulitis in order to determine factors associated with prolonged hospital stay and mor-
tality, as well as health services use by these patients. Methods: Records from the national database
of hospital discharges, which encompasses all hospitalizations across Canada, excluding Quebec
and the territories, were analyzed. All patients from 2004-2008 with an admission diagnosis of cel-
lulitis (ICD code “L03”) were included in the study. Factors associated with mortality and pro-
longed hospital stay (defined as greater than 7 days) were analyzed in univariate and multivariate
analysis through logistic regression and are expressed as odds ratios (OR). Results: During the five-
year study period, there were 65,454 patients hospitalized for cellulitis. Majority were males (54%),
and the average age at admission was 55.5 years (SD 23.9). Mortality during the admission was
about 1%, and the average length of hospital stay was 7.1 days. The most common comorbid con-
dition among patients was diabetes (8.4%), followed by congestive heart failure (3%). Consulting
services were used in 39% of hospital admissions. Factors associated with prolonged hospital stay
included female gender, advanced age, comorbid congestive heart failure, admission to or consul-
tation by a surgical service, and dermatology consultation (OR 4.5, 95% 3.9-5.2). Factors associ-
ated with mortality were male gender, advanced age, the presence of any comorbidity, surgical con-
sultation and infectious disease consultation. Interpretation: Cellulitis is responsible for a large
number of hospital admissions in Canada. The elderly and patients with comorbidities are at increased
risk for longer hospital stay and death. Cellulitis may represent a heterogenous group of conditions
and therefore frequently requires multidisciplinary approach as evidenced by high use of consult-
ing services.
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Association between the type and length of tumor necrosis factor (TNF) inhibitor therapy and
myocardial infarction (MI) risk in psoriasis
JJ Wu,1 KT Poon2 and JD Bebchuk2 1 Dermatology, Kaiser Permanente Los Angeles Medical
Center, Los Angeles, CA and 2 Research and Evaluation, Kaiser Permanente Southern
California, Pasadena, CA
We sought to assess whether the type of TNF inhibitor therapy (soluble receptor versus monoclonal
antibody) has an effect on the association of MI risk, and determine whether length of TNF inhibitor
therapy has an effect on the association of MI risk. This was a retrospective cohort study from Jan-
uary 1, 2004 and November 30, 2010 of at least 3 ICD9 codes for psoriasis (696.1) or psoriatic
arthritis (696.0) without antecedent MI. In the 3 subgroups of TNF inhibitors, 976 received etaner-
cept only; 217 received monoclonal antibody only; and 480 received etanercept or monoclonal
antibody. In the Cox proportional hazards analysis, etanercept only (HR, 0.53; 95% CI, 0.31-0.92)
was associated with a significant reduction of MI risk compared to topical agents, and monoclonal
antibody only (HR, 0.25; 95% CI, 0.06-1.03) and etanercept or monoclonal antibody (HR, 0.53;
95% CI, 0.27-1.06) were associated with a non-significant reduction of MI risk compared to topi-
cal agents. Using year 1 as reference, those who received TNF inhibitor therapy at year 2 (HR, 0.71;
95% CI, 0.19-2.67) had a non-significant reduction of MI risk; and those who received TNF inhibitor
therapy at year 3 (HR, 1.51; 95% CI, 0.52-4.35) and at year 4 (HR, 1.25; 95% CI, 0.50-3.11) had a
non-significant increase of MI risk. Treatment with etanercept compared to treatment with topical
agents, was associated with a significant decreased risk of MI in psoriasis patients. Treatment with
monoclonal antibody only and etanercept or monoclonal antibody, compared to treatment with
topical agents, was associated with a non-significant decreased risk of MI risk in psoriasis patients.
There was a trend that those treated with TNF inhibitors at year 3 or 4 had a non-significant increased
risk of MI compared to those who were treated with TNF inhibitors at year 1.
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Designing the ‘molluscum contagiosum diagnostic tool for parents’ (MCDTP)
JR Olsen,1 NA Francis,1 J Gallacher1 and V Piguet2 1 Cochrane Institute of Primary Care and
Public Health, Cardiff University, Cardiff, United Kingdom and 2 Department of Dermatology
and Wound Healing, Cardiff University, Cardiff, United Kingdom
Molluscum Contagiosum (MC), a member of the poxvirus family, is a viral disorder of the skin and
mucous membranes characterised by discrete, single or multiple flesh coloured papules. The virus
can lead to discomfort and pain, in children there can also be symptoms of pruritus, erythema,
inflammation and super infections in some cases. Lesions are diagnosed upon sight due to their dis-
tinct appearance, in unusual and rare cases they may be referred for biopsy. This study aims to design
a self diagnostic tool for parents. A two phased approach was conducted, firstly nine dermatolo-
gists were interviewed to establish the key diagnostic features of MC. Interviews were tabulated
and grouped by key themes. Medical Illustrations were selected, and dermatologists were asked to
choose those which were most representative of typical lesions. The tabulated findings from inter-
views were then discussed with a patient representative, dermatology specialist and school nurse
to produce clear wording in a lay language, also maintaining the key diagnostic elements. The sec-
ond phase of the study piloted a draft version of the MCDTP at a local parent group (n=10) to deter-
mine whether it was clear and understandable. The following themes were identified for the diag-
nosis of MC; appearance, geographical site, symptoms, and natural history. A colour booklet was
produced which used four images, accompanied with key text highlighting the features of MC. The
MCDTP is a well designed and piloted tool to allow those without a clinical background to diag-
nose MC in children. The authors specifically designed this tool as a recruitment aid for a cohort of
children over a large geographical area. Before the MCDTP can be used, the diagnostic accuracy
of parental use needs to be determined in a validation study against a gold standard assessment.
Once validated the MCDTP will also have uses for parents to allow self-diagnosis, and when accom-
panied with information about MC, may reduce primary care consultations for MC.
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Thanakha and its dermatologic uses in Myanmar (Burma)
EV Seiverling1 and HT Ahrns2 1 Dermatology, The Vancouver Clinic, Vancouver, WA and 2
Family Medicine, Oregon Health and Science University, Portland, OR
Recent geopolitical changes in Myanmar have resulted in new opportunities to study skin health
and disease in a previously isolated population. This cross-sectional study investigated the derma-
tologic uses of thanakha in Myanmar. Used by Burmese people for over 2,000 years, thanakha pow-
der is produced by grinding the bark of Hesperethusa crenulata or Naringi crenulata trees on a round
slab called a kyuak pyin. The powder is then mixed with water to form a thin yellow paste that is
applied directly to the skin. We conducted semi-structured interviews with 25 Burmese persons who
wear thanakha. Participants were both men and women, age 12-55, and represented three differ-
ent regions of Myanmar. Nine distinct dermatologic uses were identified: photoprotection, acne
treatment and prevention, skin lightening, skin cooling, aesthetics (make-up), rhytid reduction, pru-
ritis relief, scar reduction, and odor prevention. Our study determined that in Myanmar, thanakha
is being used daily for treatment and prevention of some the most prevalent dermatologic condi-
tions. As travel restrictions to Myanmar diminish, further research should investigate the efficacy
and safety of thanakha for various dermatologic conditions.
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Alcohol intake is associated with increased risk of squamous cell carcinoma of the skin:
Prospective cohort study
S Siiskonen,1,2 J Han,2,3,4 T Li,3 T Nijsten1 and A Qureshi2,3 1 Department of Dermatology,
Erasmus MC, Rotterdam, Netherlands, 2 Clinical Research Program, Department of
Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 3
Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s
Hospital, Harvard Medical School, Boston, MA and 4 Department of Epidemiology, Harvard
School of Public Health, Boston, MA
The objective of this study was to investigate the association between alcohol intake and the inci-
dence of cutaneous squamous cell carcinoma (cSCC). Multivariate Cox survival models with time-
dependent exposure and covariates were used to estimate relative risks (RRs) and 95% confidence
intervals (CIs) in three separate cohorts of U.S. women and men. The results were then meta-ana-
lyzed. A total of 174,998 women and 48,140 men participating in the Nurses’ Health Study, Nurses’
Health Study II and Health Professionals’ Follow-up Study were followed for up to 28 years. Infor-
mation on alcohol intake and covariates was collected at baseline and updated several times dur-
ing the follow-up. During a follow-up of 4,234,416 person-years, 2,938 histopathologically veri-
fied, incident invasive cSCC and 1,590 cSCC in situ were identified. Alcohol intake was significantly
associated with an increased risk of invasive cSCC in all three cohorts. A significant dose-response
relationship was observed: each additional drink (12.8 gram of alcohol) per day was associated with
22% increased risk of invasive cSCC (RR 1.22, 95% CI 1.13-1.31) and with 14% increased risk of
cSCC in situ (RR 1.14, 95% CI 1.04-1.26). White wine consumption ≥5 times a week was signifi-
cantly associated with an additional risk of invasive cSCC (RR 1.31, 95% CI 1.09-1.59). The results
of this large prospective cohort study indicate that even a moderate consumption of alcohol increases
the risk of developing cSCC in a dose-dependent manner. Our results are still to be replicated in
other large cohorts.
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Excellent reliability and validity of a novel Epidermolysis Bullosa Disease Activity and Scar-
ring Index (EBDASI) compared to two other outcome measures
CH Loh,1,6 J Kim,1,6 JC Su,2 BS Daniel,3,6 SS Venugopal,4,6 LM Rhodes,1 L Intong,1,6 M Law5 and
DF Murrell1,6 1 Dept Derm, St George Hospital, Sydney, NSW, Australia, 2 Dept Paeds, Univ
of Melbourne, Melbourne, VIC, Australia, 3 Dept Medicine, St Vincent’s Hospital, Sydney,
NSW, Australia, 4 Dept Derm, Westmead Hospital, Sydney, NSW, Australia, 5 Kirby Institute,
Univ of NSW, Sydney, NSW, Australia and 6 Faculty of Medicine, Univ of NSW, Sydney, NSW,
Australia
Current outcome measures for epidermolysis bullosa (EB) do not distinguish disease activity from
damage, hence they cannot measure changes from interventions well in clinical trials. We aimed
to devise an Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI), which could score
activity separately from scarring and to compare its reliability and validity against the Birmingham
EB Score (BEBS), using the Physician’s Global Assessment Scale (PGA) as a reference measurement.
Content validity was established by including all possible physical complications of EB, and the
methodology from the previously validated Pemphigus Disease Area Index was adapted to create
the EBDASI and piloted on several EB patients. For validation, 16 EB patients (7 EBS, 2 JEB, 5 DDEB,
2 RDEB) were scored separately on the same occasion by five EB experts using the EBDASI, BEBS
and PGA scales, each rescoring two patients to assess intra-rater reliability. For inter-rater assess-
ment, the intraclass correlation coefficients (ICCs) for overall total scores were: EBDASI 0.964,
BEBS 0.852, and PGA 0.873. For intra-rater reliability, the ICCs and 95% confidence intervals
were: EBDASI 0.994(0.976-0.998), BEBS 0.926(0.748–0.981), and PGA 0.932(0.764–0.982). Scat-
ter-plots showed that EBDASI distinguished scores better at lower severities than BEBS and PGA.
Bland Altman plots showed that EBDASI had far less intra-rater variability than BEBS and PGA. The
EBDASI demonstrated excellent reliability and validity, and was found to be superior to BEBS. As
EBDASI measures activity separately from scarring, it should be a very useful outcome measure for
trials of novel therapies in EB.
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Development of a disease registry for autoimmune bullous diseases: Initial analysis for the
pemphigus vulgaris subset
AA Shah,1 D Sirois,2 V Werth,3 W Zrnchik,4 K Seiffert-Sinha1 and AA Sinha1 1 University at
Buffalo, Buffalo, NY, 2 New York University, New York, NY, 3 University of Pennsylvania,
Philadelphia, PA and 4 IPPF, Sacramento, CA
Pemphigus vulgaris (PV) is a potentially life threatening autoimmune blistering disorder with an inci-
dence of 0.5-5 per 100,000. Collecting large data sets in PV is difficult due to the limited number
of patients available for study. There is a need for the development of a unified disease registry to
bridge the gaps in knowledge regarding epidemiology, disease manifestation, and treatment out-
comes that can be accessed by clinicians and researchers worldwide. In 2010, the International
Pemphigus and Pemphigoid Foundation (IPPF) established a web-based disease registry to facilitate
the collection of large-scale clinical data, and ultimately biological samples from registry patients
for study purposes. We present an initial analysis of clinical data collected from 4/14/2010 –
11/20/2011. A total of 599 patients with autoimmune bullous diseases enrolled, 393 of which had
PV. The PV registrants had a female:male ratio of 2.54:1, with an average age at diagnosis of 45.67
± 14.01 years, a Caucasian majority (73.5%), with most patients living in the US at the time their
illness began (77.1%). 215 PV patients reported having lesions at the time of the survey (45% mucosal
only, 30% mucocutaneous, and 25% cutaneous only manifestations). PV patients reported a con-
siderable delay in diagnosis after the development of initial symptomatology (>3 months=69.5%;
>6 months=36.1%; >12 months=13.5%). 18.8% of patients reported a coexisting autoimmune dis-
ease. Of all PV patients, 91 were off therapy, 115 on minimal therapy, and 187 on more than min-
imal therapy, as defined by consensus guidelines. We found significant differences between male
and female patients in their lesion profile, delay in diagnosis, and coexisting autoimmune disease
status. This initial analysis highlights the value of a disease registry for epidemiologic data mining
and provides a resource for future studies linking basic research data with defined clinical vari-
ables.
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Environmental and behavioral risk factors for melanoma among young women in the United
States
JF Moreau,1 LK Ferris3 and DG Winger2 1 University of Pittsburgh School of Medicine,
Pittsburgh, PA, 2 Clinical and Translational Science Institute, University of Pittsburgh,
Pittsburgh, PA and 3 Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA
The incidence of cutaneous melanoma in young women is rising at an alarming rate. To better under-
stand this increase, we sought to identify associations between socioeconomic variables and health
behaviors and melanoma severity at diagnosis among women ages 21-39. Cutaneous melanoma
data reported by 18 Surveillance Epidemiology and End Results cancer registries (2000-2009) was
merged with county-level socioeceonomic status (poverty level, household income, high school
non-completion) and health behavior (Pap smear use) estimates obtained from the US Census bureau
and national health behavior surveys. We used multivariable logistic regression to generate odds
ratios (OR) of invasive, non-localized, and >1 mm thick melanoma using county-level estimates,
demographic traits, and tumor characteristics as predictors. High school non-completion rate above
the US mean was consistently associated with melanoma severity at diagnosis (OR [95% CI] of inva-
sive melanoma: 1.29 [1.18-1.41], non-localized disease: 1.29 [1.07-1.56], and depth >1mm: 1.24
[1.10-1.42]). The same was true for non-white race (OR [95% CI] of invasive melanoma: 1.45 [1.09-
1.93], non-localized disease: 1.91 [1.57-2.91], and depth >1mm: 2.09 [1.51-2.92]). Scalp/neck,
truncal, and site NOS melanomas were associated with higher odds of invasive melanoma (p<.001),
and site NOS melanomas were associated with higher odds of non-localized disease (p<.001).
Median income above the US mean was associated with lower odds of invasive melanoma (OR
[95% CI]: 0.78 [0.71-0.85]). Pap smear testing rate above the US mean was associated with a lower
odds of melanoma >1mm deep (OR [95% CI]: 0.87 [0.78-0.98]). Our results suggest that high school
completion is the socioeconomic factor most associated with melanoma severity at diagnosis among
women ages 21-39. This information can be used to help improve the design of melanoma pre-
vention efforts targeting this population.
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Measuring the severity of topical 5-fluorouracil toxicity
K Korgavkar,1,3 M Xiong,1,3 K Marcolivio,1,2 R Lew,2 E Firoz,3 M Weinstock1,2,3 and . VAKCC Trial
Group1,2 1 Dermatoepidemiology Unit, VA Medical Center, Providence, RI, 2 VA Cooperative
Studies Program, Boston, MA and 3 Dermatology, Alpert Medical School of Brown University,
Providence, RI
The VA Keratinocyte Carcinoma Chemoprevention Trial (VAKCC Trial) evaluates topical 5-fluorouracil
(5-FU) for chemoprevention of basal and squamous cell carcinomas. This drug is known to cause
cutaneous toxicity including erythema, tenderness, flaking, and crusting/erosions. We sought to
develop a reliable scale to measure toxicity from photographs, and to investigate correlation between
the scale and patients’ self-reports. Photos of 100 participants, about half of whom had applied 5-
FU, were reviewed by 3 raters blinded to treatment. A scale, anchored by reference images, was
created for erythema and crusting/erosions, the readily visible signs of toxicity. For each pair of raters
agreement was assessed using the concordance correlation coefficient (CCC), Pearson correlation
coefficients (R), and the weighted kappa statistics (κ). In addition, each participant reported a self-
assessment of redness, itching, burning, soreness, crusting/erosions, scaling/flaking, and swelling.
Redness and crusting/erosions assessed by the patient were compared to erythema and crusting/ero-
sions from the photographs. For photo grading vs. self-report, values for CCC for erythema and crust-
ing/erosions were 0.35 and 0.55 respectively and values for R were 0.56 and 0.65. For pairwise
agreement among 3 raters, values for CCC were 0.84, 0.87, and 0.92, values for R were 0.87, 0.92,
and 0.92 and values for κwere 0.65, 0.68, and 0.76. This scale provides a reliable method of assess-
ing severity of topical 5-FU toxicity. Evaluation of toxicity from the photographs also correlates
with self-report.
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Dense genotyping of six atopic dermatitis and 180 autoimmune risk loci in 2,425 atopic der-
matitis patients
H Baurecht,1 E Rodríguez,1 D Ellinghaus,2 J Esparza-Gordillo,3,4 C Gieger,5 S Schreiber,2 Y Lee,3,4
A Franke2 and S Weidinger1 1 Department of Dermatology, Allergology, and Venerology,
University Hospital Schleswig-Holstein, Kiel, Germany, 2 Institute of Clinical Molecular
Biology, Christian-Albrechts-University, Kiel, Germany, 3 Pediatric Pneumology and
Immunology, Charité, Berlin, Germany, 4 Max-Delbrück-Centrum (MDC) for Molecular
Medicine, Berlin, Germany and 5 Institute of Genetic Epidemiology, Helmholtz Centre
Munich, Neuherberg, Germany
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases, with a poly-
genic, multifactorial nature. To date, genome-wide association studies have established six suscep-
tibility loci. However, the causal variation at these loci remains unknown. To better define risk vari-
ants and identify additional susceptibility loci previously implicated in other autoimmune (AI)
diseases, we performed a fine-mapping and association study using 2,425 German AD cases and
5,449 German population controls. All samples were genotyped on the ImmunoChip, a custom
high-density array containing 195,806 SNPs and 718 small insertions/deletions across 186 distinct
AI risk loci, including the six known AD susceptibility loci and the HLA region. At these loci, the
array contains all known SNPs in the dbSNP database, from the 1000 Genomes Project (release of
Feb. 2012), and from other AI disease resequencing efforts, therefore providing a powerful means
of fine-mapping known AI loci. Following quality control, 128,830 polymorphic markers were avail-
able for association analysis. Principal component analysis revealed no marked differences in ances-
try between cases and controls. We observed that 132 SNPs within non-HLA risk loci reached
genome-wide significance (P<5x10-8) in the screening phase. For each locus, we investigated the
existence of multiple independent association signals. Replication of the most strongly associated
SNPs (n=39) with P<10-4 in 7,196 cases and 15,480 controls from 4 independent case-control sets
revealed 6 novel AD risk loci.
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Predictors of subsequent BCC by body site in the VATTC trial
MY Xiong,1,2 MA Weinstock1,2,3 and . VATTC Trial Group1 1 Dermatoepidemiology Unit, VA
Medical Center, Providence, RI, 2 Dept. of Dermatology, Alpert Medical School of Brown
University, Providence, RI and 3 Dept. of Dermatology, Rhode Island Hospital, Providence, RI
Basal cell carcinoma (BCC) is the most common skin cancer in the United States today, and patients
who have had a previous BCC are likely to develop subsequent ones over time. Although risk fac-
tors for BCC on the face and ears have been extensively studied, predictors of BCCs on other parts
of the body have not. We thus sought to evaluate risk factors for development of subsequent BCC
on areas of the body besides face and ears. We studied a high-risk population of 1,131 mostly
male, Caucasian, elderly veterans in the Department of Veterans Affairs Topical Tretinoin Chemo-
prevention (VATTC) Trial. We employed multivariate Cox and logistic regression in order to deter-
mine predictors of BCC. We then performed analysis of variance (ANOVA) to explore differences
in BCC risk based on body site. There were a total of 335 participants (29%) who developed a BCC
on the non-face/ears during the study. The 1, 3, and 5-year cumulative risks of non-face/ears BCC
were 11%, 29%, and 41%, respectively. The number of BCCs in the 5 years prior to enrollment was
the most important independent predictor for BCCs on the non-face/ears (p < 0.001), as it had been
for BCCs on the face/ears. In addition, a history of ever use of 5-fluorouracil (5-FU) and occupa-
tional sun exposure below age 30 were positive predictors. In contrast, use of ACE inhibitors or ARBs
during the study was associated with reduced risk. Age (per decade) was the most important pre-
dictor for site of BCC (OR = 1.46, p = 0.003 for face/ears vs. rest of body; OR = 1.46, p = 0.002 for
extremities vs. trunk). The mean ages of BCC on the face/ears, neck, scalp, trunk, and extremities
were 72, 72, 69, 68, and 69, respectively. This study documents the key risk factors for subsequent
BCC in this very high-risk population.
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Second primary malignancies in patients with history of soft tissue tumors from the SEER data-
base 
SH Yu,1 DE Kurlander1 and JS Bordeaux1,2 1 Case Western Reserve University School of
Medicine, Cleveland, OH and 2 Dermatology, University Hospitals Case Medical Center,
Cleveland, OH
We sought to determine risk of subsequent primary malignancies after soft tissue tumor (STT) diag-
nosis. The Surveillance, Epidemiology, and End Results (SEER) database was used to compare the
risk of STT patients developing subsequent primary malignancies (SPMs) compared to the general
population. STTs and SPMs were classified according to guidelines provided by the World Health
Organization (WHO), which categorized STTs as follows: vascular, perivascular, skeletal muscle,
adipocytic, chondro-osseous, fibrocytic/myofibrocytic, so-called fibrohistiocytic, smooth muscle,
and uncertain differentiation. Of the 40,697 patients diagnosed with soft tissue tumors, 3,445 devel-
oped an SPM. 2835 developed 1 SPM, 253 developed 2 SPMs, and 33 developed 3+ SPMs. Besides
second primary STTs, other cancer sites with a significantly increased risk (O:E) were neoplasms of
the retroperitoneum (7.88; 95% CI: 4.41-12.99), bones and joints (8.26; 95% CI: 5.24-12.49),
melanoma (1.67; 95% CI: 1.40-1.97), and other non-epithelial skin cancers (2.32; 95% CI: 1.42-
3.59). The risk of non-Hodgkin lymphoma (extranodal) (11.47; 95% CI: 10.28-12.75) and acute
myeloid leukemia (AML) (2.79; 95% CI: 2.07-3.68) was also increased. The risk of developing
SPMs was dependent on STT classification, and the risk for each were as follows: vascular (2.68;
95% CI: 2.52-2.85), skeletal muscle (2.26; 95% CI: 1.62-3.08), chondro-osseuous (1.72; 95% CI:
1.36-2.14), fibrocytic/myofibrocytic (1.26; 95% CI: 1.07-1.47), uncertain differentiation (1.24; 95%
CI: 1.10-1.40), so-called fibrohistiocytic (1.14; 95% CI: 1.05-1.23), and adipocytic (1.10; 95% CI:
1.01-1.19). There was no significant increased risk for developing SPMs after a smooth muscle
derived STT (1.03; 95% CI: 0.95-1.12), and none of the secondary neoplasms considered devel-
oped after a perivascular STT. This study showed that there was an increased risk of SPM after STT
diagnosis and treatment. The excess risk was specific to each secondary cancer site.
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Milk: An endocrine mTORC1-driving anabolic signal transduction system of mammalian
evolution promotes diseases of Western civilization like acne
BC Melnik University of Osnabrück, Dermatology, Environmental Medicine and Health
Theory, Osnabrück, Germany
Recent epidemiological evidence points to an association between increased body mass index (BMI)
and risk of acne, eczema, psoriasis as well as melanoma and nonmelanoma skin cancer. Increased
BMI is the clinical correlate of enhanced activity of the nutrient-sensitive kinase mTORC1 (mam-
malian target of rapamycin complex 1). Western diet, typically composed of high glycaemic load
and high milk and dairy product consumption, is closely linked to high BMI and metabolic aber-
rations, especially insulin resistance. Milk, the growth-promoting feeding system of mammals, pro-
duced by the well-conserved mammalian lactation genome, functions as a signal transduction sys-
tem driving anabolic mTORC1 signalling. Milk fulfills its biological function by providing highly
insulinotropic branched-chain amino acids and its intrinsic ability to raise insulin and IGF-1 plasma
levels, which are important activators of mTORC1, the central cellular promoter of cell growth and
proliferation and suppressor of autophagy. Age-related diseases of Western civilization have recently
been recognized as mTORC1-driven diseases, especially obesity, type 2 diabetes mellitus and can-
cer. Thus, milk/mTORC1-driven metabolic aberrations may not only play a pivotal role in the patho-
genesis of acne but most likely in the development of other common dermatological diseases,
especially eczema, psoriasis, and melanoma and nonmelanoma skin cancer.
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Personal history of prostate cancer and increased risk of incident melanoma in US men
W Li,1,2 A Qureshi,1 A Goldstein,2 E Giovannucci,1 M Stampfer1 and J Han1 1 Harvard Medical
School, Boston, MA and 2 National Institutes of Health, Rockville, MD
Steroid hormones, particularly androgens, play a major role in prostatic carcinogenesis. Personal
history of severe acne has been associated with an increased risk of prostate cancer. One recent
study indicated severe teenage acne as a novel risk factor for melanoma, suggesting a possible rela-
tionship between the history of prostate cancer and risk of melanoma. We prospectively evaluated
the association between prostate cancer and risk of subsequent melanoma among U.S. men. 42420
participants were included from the Health Professionals’ Follow-up Study over a 24-year period.
Prostate cancer diagnosis was confirmed using pathology reports. Skin cancers, including melanoma
and non-melanoma skin cancer (NMSC), were reported biennially and the diagnosis of melanoma
was pathologically confirmed. We calculated the Hazard Ratios (HRs) of melanoma associated with
history of prostate cancer. To address the potentially increased surveillance among those with his-
tory of cancer, we evaluated the risk of NMSC by history of prostate cancer, as well as risk of melanoma
by history of other cancers. We identified 540 melanoma cases from 1986 to 2010. Personal his-
tory of prostate cancer was associated with a significantly increased risk of melanoma with multi-
variate-adjusted HR of 1.81 (95% CI, 1.30-2.50). Although we also observed a slightly increased
risk of NMSC by personal history of prostate cancer (HR=1.13, 95% CI=1.05-1.22), the difference
in the magnitude of the association between melanoma and NMSC was highly significant (P for
heterogeneity=0.006). We did not find an increased risk of melanoma by personal history of other
cancers. In conclusion, personal history of prostate cancer is associated with an increased risk of
developing melanoma, which may not be due to detection bias. Elevated androgen levels associ-
ated with acne may contribute to this association which requires functional studies to clarify.
527
Evaluation of AJCC, UICC, and Brigham and Women’s Hospital tumor staging for cutaneous
squamous cell carcinoma
PS Karia,1 DP Harrington,2 A Jambusaria-Pahlajani,3 GF Murphy,4 AA Qureshi1 and CD Schmults1
1 Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 2
Biostatistics, Harvard School of Public Health, Boston, MA, 3 Dermatology, Mayo Clinic,
Jacksonville, FL and 4 Pathology, Brigham and Women’s Hospital, Harvard Medical School,
Boston, MA
Although most cutaneous squamous cell carcinomas (CSCC) have an excellent prognosis, there is
a high-risk tumor subset with an increased risk of metastasis and death. However, high-risk CSCC
has not been consistently defined, nor associated prognosis estimated. Therefore, clinicians cur-
rently have little evidence to guide decisions regarding nodal staging and adjuvant therapy. The
current study was undertaken to evaluate the 2010 American Joint Committee on Cancer (AJCC),
2010 International Union Against Cancer (UICC), and 2013 Brigham and Women’s Hospital (BWH)
tumor (T) staging systems for cutaneous squamous cell carcinoma (CSCC). Primary CSCCs diag-
nosed 2000-2009 at BWH (n=1,818) were assigned AJCC, UICC, and BWH T stages. Life tables of
poor outcomes (local recurrence LR, nodal metastasis NM, and disease-specific death DSD) were
constructed and analyzed. In AJCC staging, poor outcomes were clustered in T2 with 72% of LR,
82% of NM, 67% of DSD occurring in T2 cases. In UICC staging, most poor outcomes occurred in
T1 and T2 including 81% of LR, 67% of NM, and 50% of DSD. In BWH staging, only 6% of CSCCs
were in the upper 2 stages (T2b and T3) but they accounted for the majority of LR, NM, and DSD
(53%, 76%, and 83% respectively). While ten year incidences of LR, NM, and DSD were low for
low-stage tumors [BWH T1/T2a: 1.3% (1-2%), 0.5% (0-1%), and 0.2% (0-0.5%) respectively], they
were significantly higher for high-stage cases [BWH T2b/T3: 23% (16-31%), 23% (16-31%) and
14% (8-21%) respectively]. UICC and AJCC staging for CSCC may be suboptimal as most poor out-
comes occur in low T stages (T1 and T2). In BWH staging, the majority of poor outcomes occur in
the 6% of tumors that are T2b/T3. These stages define a high-risk group which may be the focus of
further study of staging and adjuvant therapy.
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Moderate to severe psoriasis is associated with an increased risk of chronic and end stage
renal disease
S Wang,1 J Wan,1 K Haynes,2 D Shin,1,2 MR Denburg3,4 and JM Gelfand1,2 1 Dermatology,
University of Pennsylvania, Philadelphia, PA, 2 Center for Clinical Epidemiology and
Biostatistics, University of Pennsylvania, Philadelphia, PA, 3 Nephrology, The Children’s
Hospital of Philadelphia, Philadelphia, PA and 4 Nephrology, University of Pennsylvania,
Philadelphia, PA
Elevated uric acid from high epidermal turnover and chronic inflammation in psoriasis may be
toxic to renal tubules. Small studies suggest an increased risk of nephropathy in psoriasis patients.
We investigated the risk of chronic kidney disease (CKD) and end stage renal disease (ESRD) in
patients with psoriasis via a population-based cohort study using The Health Improvement Network,
a large UK medical records database. Subjects 18-90 years old with psoriasis identified by vali-
dated medical codes (135,035 with mild, 8,646 with moderate-severe disease as defined by psori-
asis treatment patterns) were compared to 716,071 patients without psoriasis, matched on age, prac-
tice and time of visit. Previously validated algorithms using medical codes and serum creatinine
data were used to define moderate to advanced CKD. In Cox regression analysis, psoriasis was
associated with an increased risk of incident CKD after adjusting for traditional risk factors (age,
sex, diabetes, hypertension, cardiovascular disease, hyperlipidemia, and body mass index) (hazard
ratio (HR): 1.05, 95% CI 1.03 – 1.08). The increased risk was confined to the moderate-severe
group (HR: 1.94, 95% CI 1.83 – 2.06) and not observed in the mild group (HR: 1.00, 95% CI 0.97
– 1.02). Patients with moderate-severe psoriasis also had a greater than 4-fold increased adjusted
risk of incident ESRD (HR: 4.36, 95% CI 3.04 – 6.25). The findings persisted in multiple sensitivity
analyses including when controlling for NSAID use. Our results suggest that moderate-severe pso-
riasis is a risk factor for developing CKD and ESRD, which has important clinical and mechanistic
implications for the research and care of psoriasis patients.
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Ten-year publication trends in dermatology in mainland China
S Xin,1 JA Mauro,2 TT Mauro,3 PM Elias3 and M Man1,3 1 Skin Physiology Res, Dalian Skin
Disease Hosp, Liaoning, China, 2 Keystone Strategy Grp, Brisbane, CA and 3 Dermatology, VA
Med Ctr/UCSF, San Francisco, CA
Background: Since its reform in 1978, China has been experiencing huge changes in many aspects
of biomedical research, including dermatologic research. However, how China’s economic and
intellectual development has affected the publication trends in dermatology, which could mirror
scientific development in dermatology and other fields, is unknown. Materials and Methods: In the
present study, we analyzed the dermatology publication trends from 2002 to 2011 in mainland
China. All data were obtained from www.pubmed.com. Results: The number of publications increased
10-fold over the 10-year period, correlating positively with the increase in gross domestic product
per capita during that period. A total of 1,231 articles from mainland China were published in Eng-
lish in 251 journals between 2002 and 2011. A total of 129 journals published only one paper from
Chinese departments of dermatology. Over 60% of articles were original research and 21.7% were
case reports. Among the journals that published dermatology papers from dermatology departments
in mainland China, the most common one was the Journal of Clinical & Experimental Dermatol-
ogy, which published 5.9% of all papers (73). 2.7% (33) papers were published in the Journal of
Investigative Dermatology, the most highly-rated dermatological journal. Conclusions: The results
suggest that the number of publications in the dermatological field increased markedly in mainland
China over the last 10 years. The dramatic increase in publications can be attributed, at least in
part, to significant improvements in economic conditions in mainland China.
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Burden-of-illness in moderate-to-severe psoriasis subjects seeking treatment: An overall descrip-
tive assessment
C Schaefer,1 JC Cappelleri,2 J Cole,3 S Guenthner,4 J Fowler,5 S Johnson6 and C Mamolo2 1
Covance Inc, Gaithersburg, MD, 2 Pfizer Inc, Groton, CT, 3 Covance Inc, San Diego, CA, 4
The Dermatology Center of Indiana, Plainfield, IN, 5 University of Louisville, Louisville, KY and
6 Johnson Dermatology, Fort Smith, AR
This observational study was designed to evaluate the humanistic and economic burden of moder-
ate-to-severe plaque psoriasis (MSPP). Two hundred adult subjects actively seeking treatment for
MSPP enrolled in 9 sites in the United States. Consented subjects who met inclusion/exclusion cri-
teria answered questions regarding their disease (e.g., symptoms, treatment, costs) and question-
naires including the SF-12, EQ-5D, Dermatology Life Quality Index (DLQI), and Work Productiv-
ity and Activity Index-Psoriasis (WPAI). Results are summarized using descriptive statistics. Of the
200 subjects, 179 (89.5%) had PASI≤20, 21 (10.5%) had PASI>20 (severe); 181 (90.5%) were receiv-
ing ≥1 prescription medication for MSPP; and 120 (60.0%) were treated with a biologic. Mean scores
were slightly lower (worse) than the general US population for SF-12 physical component summary
(47.7 vs 49.7) and EQ-5D (0.82 vs 0.87), and similar for SF-12 mental component summary (49.54
vs 49.48). On DLQI, 38.5% of subjects reported at least moderate life impact due to MSPP. On
WPAI, presenteeism (mean=13.0%) and activity impairment (15.6%) were impacted more than
absenteeism (2.0%) due to MSPP. Differences by PASI (≤20 vs > 20) in DLQI, overall work, and
activity impairment were observed. These findings suggest that relatively normal levels of general
health status (SF-12, EQ-5D) can be an achievable goal in this highly treated group of subjects with
MSPP. However, in spite of treatment, a number of subjects continue to experience impairment in
aspects of functioning (DLQI, WPAI). For subjects whose MSPP makes them compromised (PASI>20),
different treatment options should be explored until better outcomes are achieved. With clearer
treatment goals it is likely a higher proportion of subjects could achieve high functional status.
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Mood states and personality traits mediate quality of life impact in chronic pruritus
SP Kini,1 E Veledar,1 S Booker1 and SC Chen1,2 1 Dermatology, Emory University, Atlanta, GA
and 2 Dermatology, Atlanta Veterans Affairs Medical Center (VAMC), Atlanta, GA
While mood disorders such as depression and anxiety have been considered highly prevalent in
patients with chronic pruritus, there is a paucity of epidemiologic data to support these conclusions.
Additionally, no studies to date have explored the relationship between the five main personality
domains—neuroticism, agreeableness, extraversion, conscientiousness, openness—as they relate
to the severity of chronic pruritus and quality of life (QoL) impact experienced by patients. A con-
venience sample of adults (≥18 years) attending the 2012 National Eczema Association (NEA) patient
conference and those enrolling via the NEA website were surveyed using the ItchyQoL (itch-spe-
cific QoL instrument), Beck Depression Inventory, State Trait Anxiety Inventory, and NEO-Five Fac-
tor Inventory (personality assessment) in this cross-sectional study. Multivariate linear regression was
performed to determine the impact of these predictor variables on the primary outcome variable,
QoL impact of pruritus, at the 0.05 level of significance. Of the 152 subjects surveyed, subjects
omitting more than 10% of the total survey responses were excluded. The final 110 subjects were
mostly (82%) female, 72% endured symptoms > 10 years and 40% reported their pruritus to be
‘severe’. After controlling for disease severity, duration, and demographic factors, depressed mood
(4.3, p <0.01), anxiety (1.32, p=.03), and the ‘neuroticism’ personality trait (1.17, p=.045) remained
significant predictors of greater QoL impact of pruritus. This study highlights that subjects with greater
depression, anxiety and neuroticism scores reported greater QoL impact, independent of pruritus
severity. It is possible that co-morbid psychological states may contribute to poor coping to itch.
Strengthened social support and coping strategies may provide an opportunity to reduce burden of
disease in these patients. Further studies incorporating a more generalizable population of itchy
patients are indicated.
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Advanced Rai stage and skin cancer tumor stage predicts outcomes of skin cancer in patients
with chronic lymphocytic leukemia
NF Velez,3 PS Karia,1 Y Guo,1 AR Vartanov,2 MS Davids,2 JR Brown,2 VA Neel3 and CD Schmults1
1 Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 2
Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA and
3 Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Skin cancer is common in patients with chronic lymphocytic leukemia (CLL). This study sought to
determine if progression of CLL, measured by advanced Rai stage (III-IV), is associated with worse
skin cancer outcomes. A 20-year retrospective study of adult patients with CLL and skin cancer,
excluding basal cell carcinoma (BCC), in two academic centers was conducted. Main outcome
measures included hazard ratios (HR) for development of poor skin cancer outcomes (local recur-
rence, nodal metastasis or death from skin cancer). 135 patients with 381 primary skin cancers were
included. Forty-one patients (30%) had an advanced Rai Stage (III-IV) at time of skin cancer diag-
nosis. Median follow-up from time of CLL and skin cancer diagnosis was 120 and 41 months respec-
tively. Skin cancer diagnoses included squamous cell carcinoma, melanoma, and Merkel cell car-
cinoma [113 (84%), 20 (15%), and 8 (6%) patients, respectively]. Thirty-seven patients (27%) suffered
a poor skin cancer outcome. Risk of dying from skin cancer was equivalent to risk of dying from
CLL (13%). On multivariate analysis, advanced Rai stage at time of skin cancer diagnosis and high
tumor (T) stage were associated with poor skin cancer outcomes [HR and 95% CI = 4.3 (2.1-11.5)
and 5.1 (2.2-8.5), respectively]. The risk of poor outcome was highest (50%; 25-75%) in those with
both high T stage and high Rai stage. The risk was elevated as well in those with high T/low Rai
(30%; 11-60%), and low T/high Rai (17%; 11-26%). Those with both low T stage and low Rai (I-II)
had a low risk of poor outcomes from skin cancer (5%; 3.3-8.9%). In CLL patients with non-BCC
skin cancer, mortality is as high from skin cancer as from CLL itself. CLL Rai stage should be con-
sidered when risk stratifying skin cancer patients, even in those with low-stage non–BCC skin can-
cers.
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Bridging dermatologists with patient advocacy groups through smartphones
AS Kourosh, ED Schoenberg, JM Dejace and PR Bergstresser Department of Dermatology,
University of Texas Southwestern Medical Center, Dallas, TX
Patient advocacy organizations in the Coalition of Skin Diseases (CSD) seek to increase their out-
reach. The heads of CSD organizations reported that less than 10% of their current patient mem-
bers were referred by physicians, and expressed goals of increasing awareness and patient referrals,
especially among young dermatologists, in order to reach and benefit a greater number of patients.
The authors created the Skin Advocate iPhone application, which refers patients to appropriate
patient advocacy organizations for skin disease and released it as a free download in the Apple
application store. The purpose of our study was to determine: (1) whether the Skin Advocate iPhone
App would increase physician awareness and referrals to patient advocacy organizations in the
Coalition of Skin Diseases (CSD) among Texas dermatologists and dermatology residents and (2)
whether it would increase patient registrations among CSD member organizations. Effects were
measured subjectively through pre- and post-intervention surveys of Texas dermatologists and res-
idents and objectively through internal analytics that tracked downloads and usage of the iPhone
app. Pre- and post-intervention registration numbers for CSD member organizations were also meas-
ured. Pre-intervention data for self-reported physician awareness and referral and pre-intervention
numbers of registrations for CSD organizations served as historical controls. Our data revealed sig-
nificant improvement in self-reported physician awareness and referrals and increased patient reg-
istrations for the CSD organizations that represented the more common diseases. The Skin Advo-
cate iPhone App improved self-reported physician awareness and referrals to CSD member
organizations. We have concluded that an iPhone app that streamlined referrals to patient advocacy
organizations for skin disease did improve self-reported physician awareness and subsequent refer-
rals to these organizations and did increase patient registrations for patient advocacy organizations,
especially for the more common skin diseases.
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High compliance but low persistency within 12 months with systemic and biologic treatments
for psoriasis in Sweden
A Svedbom,1 C Mamolo,2 J Dalen,1 JC Cappelleri,2 IF Petersson3 and M Stahle4 1 OptumInsight,
Stockholm, Sweden, 2 Pfizer Inc, Groton, CT, 3 Orthopedics, Clinical Sciences, Lund
University, Lund, Sweden and 4 Dermatology Unit, Department of Medicine, Karolinska
Institutet, Stockholm, Sweden
The purpose of this study was to analyze treatment patterns of systemic (Syst) and biologic (Biol)
therapies for psoriasis (Pso) patients in Sweden. In this retrospective study, a cohort of adults with
≥1 ICD-10 diagnosis of Pso (L40.X) was identified from two regional registries, Skåne Health Care
Register (SHCR) and VEGA, with a combined coverage of 2.8 million people (~30% of the Swedish
population). Data included all primary and secondary care visits, and all prescriptions dispensed
in Sweden from July 2005 – Sept. 2011 from the National Prescription Registry. Compliance (adher-
ence) was measured as the number of days covered by prescriptions while patients were on treat-
ment divided by the duration (in days) from initiation to discontinuation of treatment. Persistency
on treatment covered the duration of time from initiation to discontinuation of treatment; patients
were allowed to have gaps between filled prescriptions, but were defined as non-persistent if they
had a gap >60 days (the “grace period”). For Biol therapies, an undesirable treatment effect was
defined to occur at (1) up-titration of dosage, (2) augmentation with phototherapy, or (3) subse-
quent treatment with another Syst or Biol. Patients were highly compliant with both Syst (98%) and
Biol (92%) therapy; however, persistency was sub-optimal, with only 54% (Syst) and 55% (Biol) of
treated patients classified as persistent within 12 months of initiating treatment. Of the 653 patients
treated with Biol, ~30% experienced an undesirable treatment effect within 12 months of initiating
treatment. Given the chronic nature of Pso, these findings suggest that many patients with severe
Pso may cycle through available treatment options within a few years, highlighting the need for mul-
tiple effective treatment options to individualize and optimize life-long pharmacological treatment.
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The prevalence of autosomal recessive congenital ichthyosis and of transglutaminase-1 defi-
ciency in Germany: Calculation of estimates using the three-source capture-recapture method
T Hartz,1 H Hennies,2 V Oji,3 I Schmidtmann,1 K Kiekbusch,4 B Kleinow,4 K Aufenvenne,3 F Ück-
ert1 and H Traupe3 1 Institute of Medical Biometry, Epidemiology and Informatics, University
of Mainz, Mainz, Germany, 2 Cologne Center of Genomics, University of Köln, Köln,
Germany, 3 Department of Dermatology, University of Münster, Münster, Germany and 4
Selbsthilfe Ichthyose, Patient Organization, Mittenwalde, Germany
Except for Spain and Sweden no reliable data are available for prevalence of autosomal recessive
congenital ichthyosis (ARCI) in Europe. To overcome this unfortunate situation we calculated esti-
mates of prevalence of ARCI as well as of TG-1 deficient ARCI, making use of three data sources:
the national registry of the ichthyosis network NIRK that assembled data on 881 ichthyosis patients
(all types), the molecular genetic data base RoughSkin of the Köln center for genomics providing
data on 535 patients (all types) and the data base of the German patient organization for ichthyosis
(SI) comprising 468 patients (all types). The data were matched using a patient identifier (PID) gen-
erator. Prevalence of ARCI was then calculated using the three source capture–recapture method
using the log-linear-model. Information on status for TG1-deficiency was taken from the NIRK data-
base (biochemical in situ-monitoring of activity) or from the RoughSkin database (sequencing
data). We identified 639 patients diagnosed with ARCI in Germany. This means that the minimum
prevalence of ARCI in Germany, having a population of 81.726.000 is 0,78 in 100.000. Applying
the capture-recapture method that takes into account that each contributing source is incomplete,
we derive a prevalence of ARCI of 1,7 in 100.000 in Germany. For calculation of TG1- deficiency
the NIRK data set was used (biochemical data). Here 26 out of 81 investigated ARCI patients exhib-
ited TG1-deficiency meaning that the derived prevalence is 0,5 in 100.000. These numbers are
higher than previous textbook assumptions and even exceed the data for ARCI from Spain giving
1.6 in 100.000.
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Low dose aspirin is not associated with a decreased incident skin cancer risk: A population-
based cohort study among 1.2 million Dutch inhabitants
LM Hollestein,1 MP van Herk-Sukel,2 R Ruiter,1 E de Vries,1,3 RH Mathijssen,1 EA Wiemer,1
T Stijnen,4 VE Lemmens,1,3 RM Herings,2 BH Stricker1,2 and T Nijsten1 1 Erasmus University MC,
Rotterdam, Netherlands, 2 PHARMO, Utrecht, Netherlands, 3 Eindhoven Cancer Registry,
Eindhoven, Netherlands and 4 Leiden University MC, Leiden, Netherlands
Objective: To investigate the protective effect of low dose aspirin use (≤ 100 mg daily) on skin can-
cer in the Dutch general population. Methods: We conducted a population-based cohort study
with detailed information on aspirin exposure and cancer incidence using the linkage between
PHARMO and the Eindhoven Cancer Registry, including inhabitants between 1998 and 2010 above
18 years and free of cancer at baseline. A Cox model with cumulative low dose aspirin use as a
time-varying determinant was used to obtain adjusted hazard ratios (HR). Results: We included
1,063,327 non-users and 112,491 new low dose aspirin users with a mean follow up of 9.8 and
11.0 years, respectively. Ever use should not affect skin cancer risk, but was associated with an
increased risk of all skin cancers. This could be due to residual confounding and therefore we per-
formed subsequent analyses in new low dose aspirin users. Additional years of low dose aspirin use
were not associated with a decreased risk of melanoma (HR per additional year of aspirin use:
1.06, 95% confidence interval [CI] 0.96-1.17), basal cell carcinoma (BCC) (HR 1.07, 95% CI 1.01-
1.13) or other skin cancers (mainly squamous cell carcinoma) (HR 1.02, 95% CI 0.99-1.05). Long-
term use (>6 years) was also not associated with a decreased risk compared to short-term use (<2
years) for all types of skin cancer (HR melanoma: 1.31, 95% CI 0.61-2.79; HR BCC 1.24, 95% CI
1.00-1.55; HR other skin cancers; 1.92, 95% CI 1.26-2.93). Conclusion: Low dose aspirin use was
not associated with a decreased risk of skin cancer in the Dutch general population.
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Chronic pruritus and gender: Overview of differences in prevalence in clinic setting, sever-
ity and burden of disease
M Weiss and E Weisshaar Clinical Social Medicine, University Hospital Heidelberg,
Heidelberg, Germany
Chronic Pruritus (CP) (> 6 weeks) is a frequent symptom in dermatology and other diseases, such
as internal, neurological and psychosomatic/psychiatric diseases. It goes along with a high burden
of disease and impairs health related quality of life in affected patients. The term gender is under-
stood to not only include sex differences (biological aspects of women and men) but also regard-
ing social, cultural and psychological aspects of sex. Previous studies have shown statistical mag-
nitudes on CP caused by sex e.g. in prevalence. Although gender has already become an important
aspect in medical research, data on gender differences in CP are lacking. For operationalization of
gender the variables occupation/professional training were used as they are able to give informa-
tion about a patient’s gender role/social gender uncared of his/her biological sex. Data on patients
with CP visiting the itch clinic of the University Hospital Heidelberg from 2008 to 2012 were ana-
lyzed. Patients were asked to complete a questionnaire covering occurrence/characteristics of pru-
ritus as well as medical and psychosocial domains including lifestyle variables concerning pruri-
tus. We compared means and frequencies according to sex and gender. A total of 583 patients with
CP were eligible for analysis, of whom 55,6% were female. Mean age was 59,0 years (SD: 18,0).
There was no pronounced difference between age and gender/sex. 70,6% of the patients had been
suffering from CP for 1 year or longer. 53,9% of these were woman. Barely three quarters (73,8%)
claimed CP reducing health related quality of life, of these 55,1% were female. Impaired health
related quality of life was significantly associated with gender and sex. Severity of pruritus (accord-
ing to VAS) showed a significant association with only sex. Mean VAS score was 6,55 (SD: 2,4). The
collected data allow identifying gender specific outcomes in patients with CP regarding gender iden-
tity. First analyses demonstrate the need for improved gender-sensitive patient care to avoid gender
blindness.
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Effectiveness of less commonly used systemic monotherapies and common combination ther-
apies for moderate to severe psoriasis in the real world setting: results from the Dermatol-
ogy Clinical Effectiveness Research Network (DCERN)
J Takeshita,1 S Wang,1 K Callis Duffin,2 GG Krueger,2 AB Troxel,1 AS Van Voorhees1 and
JM Gelfand1 1 University of Pennsylvania, Philadelphia, PA and 2 University of Utah, Salt Lake
City, UT
Data on the effectiveness of therapies for moderate to severe psoriasis in real world settings remain
scant. We recently reported that the effectiveness of commonly used systemic therapies and pho-
totherapy is lower in the clinical setting compared to what is reported in randomized controlled tri-
als. The aim of this study was to determine the effectiveness of less commonly used systemic mono-
and common combination therapies for moderate to severe psoriasis. We conducted a cross-sec-
tional study of 371 patients with plaque psoriasis on methotrexate (mtx; reference), acitretin,
cyclosporine, infliximab, adalimumab + mtx, etanercept + mtx, or infliximab + mtx at 10 centers
in the U.S. The proportion of patients with clear/almost clear skin per Physician Global Assessment
differed among treatments: mtx (22.3%), acitretin (35.1%), cyclosporine (36.8%), infliximab (46.3%),
adalimumab + mtx (59.2%), etanercept + mtx (50.0%), infliximab + mtx (44.1%) (p<0.001). In
adjusted analyses, patients on acitretin (relative response rate 2.01, 95% confidence interval (CI)
1.18-3.41), infliximab (1.93, 95% CI 1.26-2.98), adalimumab + mtx (3.04, 95% CI 2.12-4.36), etan-
ercept + mtx (2.22, 95% CI 1.25-3.94), and infliximab + mtx (1.72, 95% CI 1.10-2.70) were more
likely to have clear/almost clear skin compared to patients on mtx, though absolute differences were
small. There were no differences in quality of life responses. Patients on infliximab were found to
have the longest treatment persistence (median 24 months, interquartile range 7-60), and >70%
were on escalated doses (>5 mg/kg every 8 weeks). Our results, though limited by cross-sectional
design, highlight the differences in effectiveness and efficacy of psoriasis therapies and emphasize
the need for longitudinal effectiveness studies.
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Improvement in precision of counting actinic keratosis after annual consensus discussion
KC Lee,1,3 R Lew2 and MA Weinstock1,2 1 Dermatoepidemiology, VA Medical Center,
Providence, RI, 2 Cooperative Studies, VA Medical Center, Boston, MA and 3 Dermatology,
Brown University, Providence, RI
Previous studies have demonstrated a lack of agreement in counting actinic keratoses (AKs) among
experienced dermatologists. We sought to determine whether cumulative consensus discussions,
held yearly for 4 years, could improve agreement among dermatologists counting AKs. A prospec-
tive, single-blind study was conducted at 4 VA Medical Centers (Palo Alto, California; Chicago, Illi-
nois; Miami, Florida; Denver, Colorado). Each year, 10 dermatologists met at one of the VA Med-
ical Centers and counted AKs on 3-5 subjects. A consensus discussion was subsequently held to
discuss discrepancies in the AK count. After the consensus meeting, dermatologists evaluated 3-5
additional subjects for AKs. The average age of the dermatologists was 47 years old (SD ±8 years),
and their average number of years in practice was 15 (±9). All subjects were male veterans with
marked dermatoheliosis serviced by the dermatology department at a VA Medical Center. Eight
subjects were examined during Year 1. Nine subjects were examined during Years 2, and 3. Six sub-
jects were examined during Year 4. There was consistent improvement in the level of agreement
among raters during the study period (pre-consensus intraclass correlation coefficient [ICC], Year 1:
0.18, Year 2: 0.27, Year 3: 0.54, Year 4: 0.78, p=.02). Post- consensus data was not available for Year
1. Post-consensus ICCs for Years 2, 3, and 4 were 0.53, 0.58, and 0.75, respectively (p=.01). These
findings suggest that improved precision of counting AKs can be achieved and sustained with
yearly consensus discussions.
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Severe allergic contact dermatitis to compound tincture of benzoin in post-surgical patients
is associated with positive reactions to fragrances and essential oils
J Fettig,1 A Sood,2 JS Taylor2 and D Murray2 1 Cleveland Clinic Lerner College of Medicine,
Cleveland Clinic Foundation, Cleveland, OH and 2 Department of Dermatology, Cleveland
Clinic Foundation, Cleveland, OH
Compound tincture of benzoin (CTB) is commonly used to increase adherence of adhesive tape to
skin after skin incisions in a variety of surgical procedures. There have been case reports of allergic
contact dermatitis to CTB; however patients are not routinely patch tested to CTB. A retrospective
chart review, including operative reports, was conducted to characterize patients with established
CTB contact allergy (n=7) in whom aimed patch testing was performed for suspected post-opera-
tive dermatitis. Most patients (85%) were female and ranged in age from 25-66 with a mean age of
47; 85% were Caucasian. Four patients had a history of atopy. Each patient underwent a surgical
procedure which was followed by a severe blistering rash at the surgical site; some patients had dis-
semination to other sites. Of the positive reactions to CTB, four were 3+ reactions, two were 2+
reactions and one was a 1+ reaction. Two patients were given antibiotics for presumed infection
and four required treated with systemic corticosteroids. Reactions to botanicals, essential oils and
fragrances were noted in all patients: five patients reacted to compositae mix 6%, four had a severe
3+ reaction to ylang-ylang oil, four reacted to majantole 5%, and four to peppermint oil. Surgical
preparations were also tested. Three patients had 1+ reactions to betadine; none were allergic to
chlorhexidine gluconate or Steri-Strips™. CTB is commonly used in post-operative patients and has
the potential to cause severe contact allergy. The lack of knowledge about this compound may cause
delay in diagnosis as well as significant post-operative morbidity. Reactions to CTB are usually severe,
may require systemic corticosteroid therapy and can be misdiagnosed as post-operative infections.
The severe nature of the allergic reactions to CTB may justify recommending that patients who
have known allergy to fragrances or essential oils avoid CTB.
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Predictors of morpheaform BCC on the face and ears in the VATTC trial
MY Xiong,1,2 MA Weinstock1,2,3 and . VATTC Trial Group1 1 Dermatoepidemiology Unit, VA
Medical Center, Providence, RI, 2 Dept. of Dermatology, Alpert Medical School of Brown
University, Providence, RI and 3 Dept. of Dermatology, Rhode Island Hospital, Providence, RI
Basal cell carcinoma (BCC) is the most common skin cancer in the United States today, and patients
who have had a previous BCC are likely to develop subsequent ones over time. Although BCCs
overall are less aggressive than other forms of skin cancer, the morpheaform subtype is particularly
concerning due to its benign, scar-like appearance and its ability to spread subclinically. We thus
sought to evaluate risk factors for development of subsequent morpheaform BCC on the face and
ears. We studied a high-risk population of 1,131 mostly male, Caucasian, elderly veterans in the
Department of Veterans Affairs Topical Tretinoin Chemoprevention (VATTC) Trial. We employed mul-
tivariate Cox regression in order to determine risk factors for time to first morpheaform BCC. We
then performed logistic regression in order to assess risk factors for morpheaform BCC relative to
other types of BCC. There were a total of 50 participants (4.4%) who developed a morpheaform
BCC during this study. The 1, 3, and 5-year cumulative risks of morpheaform BCC were 1.2%, 4.1%,
and 5.4%, respectively. The number of BCCs in the 5 years prior to enrollment was the most impor-
tant independent predictor of subsequent morpheaform BCCs (HRR=9.71, p < 0.001). In addition,
a history of ever use of 5-fluorouracil (5-FU) was a positive predictor for morpheaform BCCs (HRR
= 2.76, p = 0.013), unlike for BCCs in general (though it was for SCCs). Among individuals with
morpheaform BCCs, non-morpheaform BCCs, and no BCCs, the proportion of ever-users of 5-FU
were 38%, 20%, and 17%, respectively. This study documents the key risk factors for subsequent
morpheaform BCC in this very high-risk population. These findings raise concern that BCCs occur-
ring after 5-FU treatment may be more likely to be the morpheaform subtype.
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Lower serum vitamin D levels are associated with increased risk of eczema in US adults
T Fu, C Gamba, H Ive and JY Tang Dermatology, Stanford University School of Medicine,
Stanford, CA
Vitamin D’s immunoregulatory properties may play a role in development and severity of allergic
conditions. Research indicates an inverse relationship between vitamin D levels and severity of
eczema in children, and some studies show improved eczema symptoms following vitamin D sup-
plementation and phototherapy. We sought to determine the association between serum vitamin D
levels and eczema in U.S. adults. The 2005-2006 National Health and Nutrition Examination Sur-
vey included measurement of serum 25-hydroxyvitamin D (25(OH)D) levels and questions about
eczema. We used logistic regression to evaluate the relationship between vitamin D levels and
eczema status in subjects aged 19-49 years (N=2,839). We categorized subjects as never, ever, and
recently having eczema. Serum 25(OH)D levels of <20 ng/mL, 20.1-29.9 ng/mL, and >= 30 ng/mL
were categorized as deficient, insufficient, and sufficient, respectively. We adjusted for age, race,
gender, BMI, season of blood draw, poverty index ratio, milk intake, multivitamin use, television
and computer use, physical activity, and sun exposure, and stratified subjects by age group. Over-
all, vitamin D deficiency was significantly associated with ever having eczema (OR 2.66, 95% CI:
1.47-4.81), and vitamin D insufficiency was associated with recent eczema (OR 2.39, 95% CI: 1.00-
5.58) and ever eczema (OR 1.87, 95% CI: 1.10-3.17). Among 19-29 year-olds, vitamin D deficiency
was significantly associated with recent eczema (OR 9.57, 95% CI: 1.91-76.95) and ever eczema
(OR 6.93, 95% CI: 2.52-19.03), while vitamin D insufficiency correlated with ever eczema (OR
2.77, 95% CI: 0.86-8.86). Trends toward similar associations were also seen in older age groups.
Limitations of these results include the survey’s cross-sectional nature and self-reporting of eczema
diagnosis. In conclusion, vitamin D insufficiency and deficiency is associated with increased eczema
risk, especially in young adults. Further investigation on the effects of vitamin D supplementation
on eczema in this group is warranted.
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Increasing incidence of bullous pemphigoid in Finland
A Försti,1 J Jokelainen,2 M Timonen2 and K Tasanen1 1 Dermatology, University of Oulu, Oulu,
Finland and 2 Health Sciences, University of Oulu, Oulu, Finland
Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease. In studies based
on clinical samples the incidence of BP has varied between 2,5-21.7 per 1 000 000 inhabitants per
year, however, a British study based on a computerized general practice database reports the inci-
dence of BP as high as 42,8. Moreover, the incidence of BP has been reported to have increased
both in UK and France. The aim of our study was to study the incidence of BP in Finland and whether
it has increased also in Finland. The study material consisted of all pemphigoid patients diagnosed
in the Oulu University Hospital between years 1985-2009. The data of the disease was collected
from the patient records. The diagnosis of BP was evaluated with the following criteria: clinical fea-
tures, histopathological and immunofluorescence (IF) examinations of skin biopsies, indirect IF
analysis and BP180-ELISA. The statistical analyses were performed in STATA (Data Analysis and
Statistical Software) and PASW (Predictive Analytics SoftWare). 155 BP cases were found. In 92,9
% of the cases BP manifested in the skin and in 7,1 % both in the skin and mucous membranes.
The mean age at the diagnosis was 76,7 years. We diagnosed 24, 48, and 83 BP cases between years
1985-1989, 1990-1999, and 2000-2009, respectively. The crude incidence in the Northern Ostro-
bothnia Hospital District was 16,9 (95% CI 14,5-19,8) / 1 000 000 person-years. Using the Euro-
pean standard population as a reference the age-standardized incidence was 15 (95% CI 12-17)
new BP cases per 1 000 000 person-years. The age-standardized incidence rates in five-year peri-
ods were 14,0, 12,4, 14,2, 16,5, and 26,8 between 1985-1989, 1990-1994, 1995-1999, 2000-
2004, and 2005-2009, respectively. The incidence of BP increased 1,9 -fold (IRR 1,9, 95% CI 1,3-
2,6) in 2005-2009 compared with the mean incidence level of BP between 1985-2004. In this
population-based study with immunohistologically verified BP cases we found that the age-adjusted
incidence of BP has increased remarkably in Finland in the end of 2000s.
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Epidemiology of cutaneous lymphoma in Japan: A nationwide study of 1,871 patients
T Hamada and K Iwatsuki Dermatology, Okayama University Graduate School of Medicine,
Dentistry, and Pharmaceutical Sciences, Okayama, Japan
Most epidemiological surveys on cutaneous lymphomas (CLs) have been limited to case series
reports, mainly of single medical centers. Therefore, epidemiologic data of CLs has not been fully
evaluated in many parts of the world. To investigate the incidences of various CLs in Japan, using
epidemiological data from a nationwide registration system for CLs, and to compare the results
obtained from the present study with those from other cohorts. We analyzed the incidence pattern
of CLs from 2007 to 2011 in Japan. The present registry covers the entire nation and includes more
than 600 dermatological institutes throughout Japan. The 1,871 patients registered included 1,506
(80.5%) patients with mature T-cell and NK-cell neoplasms, 340 (18.2%) with B-cell neoplasms and
25 (1.3%) with immature hematologic neoplasms including 24 with blastic plasmacytoid dendritic
cell neoplasm. Mycosis fungoides (MF) is the most common CL subtype in the present study (750
patients, 40.1%). The proportion of MF patients with early-stage disease was 73%, similar to that
of previous studies from other cohorts. The incidence rates of adult T-cell leukemia/lymphoma (ATLL)
and extranodal NK/T cell lymphoma, nasal type (ENKL) were 15.5% and 1.8%, respectively. The
incidence rate of mature T-cell and NK-cell neoplasm in the present study was 3.5 to 9.2% higher
than in those of the United States and Europe, because of the high prevalences of ATLL and ENKL
in Japan.
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Surgical excision versus imiquimod 5% cream for basal-cell carcinoma (SINS): A multi-cen-
tre non-inferiority randomised controlled trial
HC Williams, F Bath-Hextall, M Ozolins, G Colver, W Perkins, S Armstrong and P Miller
University of Nottingham, Nottingham, United Kingdom
Basal cell carcinoma (BCC) incidence is increasing worldwide. Imiquimod cream may be useful for
people with BCC occurring in low-risk body sites, but it has not been compared head to head with
standard excisional surgery. We conducted a non-inferiority randomised controlled trial compar-
ing imiquimod 5% cream with surgical excision with a 4mm margin in 501 participants with pri-
mary nodular or superficial BCC. Primary outcome was the proportion of participants with clinical
evidence of “success”, defined as absence of initial treatment failure or signs of local recurrence at
3 years. At 3 years significantly fewer participants in the imiquimod group (83.6%) were success-
fully treated compared to the surgical group (98.4%), relative risk (RR) 0.84 (98%CI, 0.78 to 0.91),
with most imiquimod treatment failures occurring in the first year after treatment. Imiquimod could
not be said to be non-inferior to surgery at three years since it did not meet our predefined non-
inferiority criterion of RR=0.87. Significantly fewer participants in the imiquimod group were suc-
cessfully treated compared to surgery at years one and two, RR 0.88 (98%CI, 0.82 to 0.93) and RR
0.86 (98%CI, 0.80 to 0.92), respectively. More participants experienced at least moderate pain dur-
ing imiquimod treatment compared to surgery whereas less pain was experienced with imiquimod
than surgery during the follow-up period. There was no significant difference in cosmetic appear-
ance when rated by participants, but a difference in favour of imiquimod was noted by dermatolo-
gists from photographs. There were fewer treatment failures in the surgery group compared with
imiquimod and little difference in cost between them. Imiquimod cream may still be a useful treat-
ment option in primary care for small low risk superficial or nodular BCC depending on patient pref-
erence.
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Association between ultraviolet flux and risk of invasive cutaneous squamous cell carcinoma
in US men
K Nguyen,1 J Han,1,2,3 T Li2 and AA Qureshi1,2 1 Clinical Research Program, Department of
Dermatology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 2
Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s
Hospital and Harvard Medical School, Boston, MA and 3 Department of Epidemiology,
Harvard School of Public Health, Boston, MA
Previous measures of self-reported ultraviolet radiation exposure have been fraught with concerns
about recall bias. Ultraviolet flux of residence provides an estimate of ultraviolet radiation exposure
on the Earth’s surface, serving as a surrogate marker for ambient UV radiation exposure based on
an individual’s residence history. In this study, we investigated the association between UV flux of
residence and risk of invasive squamous cell carcinoma among US men. In particular, we esti-
mated cumulative UV flux as the sum of UV flux to which an individual was exposed based on
their reported state of residence. Information on 47,839 male participants with follow-up over 20
years was included from the Health Professionals Follow-up Study. In multivariate models adjust-
ing for known skin cancer risk factors, higher quintiles of cumulative UV flux were associated with
an increased risk of invasive SCC in comparison to the lowest quintile (relative risk of invasive SCC:
2.86 (95% CI: 1.52, 5.41) in the highest quintile, p value for trend<0.0001). We also evaluated
average annual UV flux and found a similar risk of invasive SCC. In this study, we found a strong
dose-response relationship between adult cumulative UV flux of residence and the risk of invasive
SCC despite adjustment for all known SCC risk factors.
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Risk of subsequent non-melanoma skin cancers in patients with prior non-melanoma skin
cancer
MR Wehner,1,2 E Linos,1 R Parvataneni,1 SE Stuart,1 WJ Boscardin3 and M Chren1,4 1 Dermatology,
University of California San Francisco, San Francisco, CA, 2 School of Medicine, Stanford
University, Stanford, CA, 3 Epidemiology and Biostatistics, University of California San
Francisco, San Francisco, CA and 4 Dermatology, San Francisco Veterans Affairs Medical
Center, San Francisco, CA
Patients with non-melanoma skin cancer (NMSC) have increased risk of subsequent NMSCs, but
information is limited about the timing and frequency of these subsequent tumors. Our goal was to
determine the risk of all subsequent NMSCs and the time interval between NMSC events after the
diagnosis of a primary NMSC. We used data from a prospective study of consecutive patients diag-
nosed with NMSC in 1999-2000 at a university practice or a Veterans Affairs clinic and followed
through 2012. We performed multiple-failure analyses using Cox proportional hazards methods
with marginal modeling to assess the probability of subsequent NMSC after any primary NMSC diag-
nosed during the follow-up time. In the 1360 patients, the mean follow-up time was 5.9 years, and
3648 subsequent NMSCs were diagnosed (mean of 0.46 per patient per year). At 1, 2, 3, 5, and 10
years after diagnosis of a primary NMSC, the probabilities of developing a subsequent NMSC were
41.8%, 57.1%, 66.3%, 76.0%, and 85.7% respectively. After adjustment for numbers of dermatol-
ogy clinic visits and biopsies, increased risk of subsequent NMSC was associated with increasing
age, male gender, history of NMSC prior to enrollment, history of HIV infection or organ trans-
plantation, and diagnosis of squamous cell carcinoma or more than one NMSC at enrollment. We
conclude that patients with NMSC are at higher risk of subsequent NMSC than previously reported:
the risk of an additional tumor is greater than 50% by 2 years and greater than 85% by 10 years
after a single NMSC diagnosis. These findings are unique because they include multiple subse-
quent tumors. They can inform patients and clinicians about prognosis and optimal screening strate-
gies, and they contribute to a growing conception of NMSC as a chronic diathesis with suscepti-
bility to multiple cancers over time.
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Incidence of nonmelanoma skin cancer in patients presenting for routine dermatological care
M Enamandram, KR Donahue, LM Duncan and AB Kimball Massachusetts General Hospital
and Harvard Medical School, Boston, MA
In light of the significant public health problem posed by skin cancer in the United States, the pur-
pose of this research is to identify the rate of skin cancer diagnosis during routine visits to the Med-
ical Dermatology clinic at Massachusetts General Hospital, a busy urban multi-provider setting. Pre-
viously, we found that approximately 9% of patients referred for urgent dermatological care were
diagnosed with biopsy proven skin cancer in our urgent access setting for same week appointments.
Medical records of patients presenting for routine dermatological care at Massachusetts General
Hospital between 03/28/2012 and 09/28/2012 were retrospectively reviewed. All patients diag-
nosed with nonmelanoma skin cancer histopathologically confirmed by skin biopsy were identi-
fied. Billing data was used to identify the number of patients evaluated in Medical Dermatology
during the study period. A total of 14,829 unique patients presented for routine dermatological
care during the study period. NMSC was definitively diagnosed in a total of 1,251 skin biopsies in
1,038 unique patients (7.0% of the population). 55% of NMSC patients were men and 45% were
women, with a mean age of 69.7 ± 13.0 years. Among NMSC identified, 61.8% were basal cell
carcinomas, 36.9% were squamous cell carcinomas; 1.3% were other non-melanoma cutaneous
tumors. The incidence of NMSC skin cancer in routine general dermatologic care is high and com-
parable with that observed in our urgent referral setting. Furthermore, the rate of skin cancer is even
greater if superficial specimens that limited a definitive diagnosis and melanoma are also included.
These findings validate the value of care provided by dermatologists and highlight the likely increas-
ing need for their diagnostic skills as the population ages in the United States.
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A market for concierge melanoma clinics may exist
E Seidler,1 E Vickery,1 E Jones,1 E Veledar1 and S Chen1,2 1 Dermatology, Emory University,
Atlanta, GA and 2 Dermatology, Veterans Affairs Medical Center, Atlanta, GA
Pigmented lesion clinics in academic centers face more demand for visits than they can usually
accommodate. Thus, we sought to determine the proportion of such visits that are additional and
fall outside of the standard-of-care frequency. We conducted a retrospective chart review from Jan-
uary 2012 to October 2010 and recorded patients’ diagnoses, date of diagnosis, follow-up visit
schedule for 2 years and demographic information. Based on follow-up schedules per diagnosis,
each visit was determined to be “standard” (conform) versus “additional.” 609 patients yielded 1,756
visits of which 14.6% qualified as “additional.” 56.4% of additional visits were in patients with inva-
sive melanoma; however, 54.8% of all visits were in patients with invasive melanoma. Controlling
for diagnosis, the relative frequency of additional visits was similar across all diagnoses: 17% with
mild to moderate dysplastic nevi, 23% with atypical mole syndrome, 17% with severely dysplas-
tic nevi or melanoma in-situ, 15% with invasive melanoma and 10% with only a family history of
melanoma. There were no significant differences (p > 0.05) between patients who had additional
visits and those who did not with regards to gender, family history of melanoma, and history of more
than one melanoma. These data demonstrate that a concierge market may exist among patients with
a history of or risk for melanoma, regardless of severity of disease. In a changing healthcare envi-
ronment, implementing concierge clinics to accommodate additional visits may serve as an inno-
vative way to meet melanoma patients’ needs.
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Malignancy risk is not demonstrated in patients with immunobullous diseases receiving
mycophenolate mofetil
LS Chan1,2 and EL Pappo1 1 Dermatology, University of Illinois Hospital and Health Sciences
System, Chicago, IL and 2 Dermatology, Jesse Brown VA, Chicago, IL
Increased risk of certain malignancies has been reported in the organ transplant patients who receive
immunosuppressants to prevent rejection. However, the same risk in patients with skin diseases
receiving immunosuppressants has not been determined. We aim to elucidate whether mycophe-
nolate mofetil (MMF), a common treatment for autoimmune blistering diseases, has an increased
risk of malignancy when used in this specific population. Towards that end, billing codes within the
university’s electronic medical record system were utilized to identify 139 patients who were diag-
nosed with an immunobullous disease, beginning in 1996 when the hospital first adopted electronic
medical records, until 2012, and a chart review was performed. All immunosuppressive drugs,
dosages, and duration of use were recorded. Cumulative doses, maximum doses, and average daily
doses were calculated. Any development of a malignancy during this time was recorded in detail.
Among the 139 patients, 91 used MMF for at least one day, 24 (26.37%) used MMF for more than
4 years, and 13 (14.29%) used MMF for over 5 years. Odds ratios and respective confidence inter-
vals were calculated to compare cancer rates in patients taking MMF for at least 4 years, or those
taking MMF for at least 5 years, with patients who were unexposed to MMF. Comparisons were
also made between the group using MMF for at least 4 or 5 years and those using MMF for shorter
duration or no MMF. Regardless which comparison, all 95% confidence intervals comparing long-
duration MMF use to short-duration MMF use or no MMF use included 1.0. Including this number
demonstrates no statistical significance between these groups and suggests no relationship or change
in odds of a patient having cancer based on duration of MMF use. This small study provides a first
analysis for the oncogenic potential of MMF as a treatment for autoimmune blistering diseases and
future large studies will help verify potential malignancy risk of MMF and promoting informed
treatment decision.
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Basal cell carcinoma incidence and associated risk factors in US women and men
S Wu,1,2 J Han,1,2,3 W Li1,2 and AA Qureshi1,2 1 Department of Dermatology, Brigham and
Women’s Hospital, Harvard Medical School, Boston, MA, 2 Channing Division of Network
Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical
School, Boston, MA and 3 Department of Epidemiology, Harvard School of Public Health,
Boston, MA
There is a paucity of data on basal cell carcinoma (BCC) in the United States as most national reg-
istries do not collect information on BCC. In this study, the authors described incidence trends and
associated risk factors for BCC in 95,743 US women from the Nurses’ Health Study (1986-2006),
and in 44,428 US men from the Health Professionals’ Follow-up Study (1988-2006). A total of 23,943
incident BCC cases were reported during follow-up. Age-adjusted BCC incidence rates increased
from 838 cases per 100,000 person-years to 1,322 cases per 100,000 person years for women, and
increased from 727 cases per 100,000 person-years to 1,813 cases per 100,000 person-years for
men. Cox proportional hazards analysis identified several strong phenotypic risk factors for BCC in
both cohorts: family history of melanoma, blonde and red hair color, higher number of extremity
moles, higher susceptibility to burn as a child/adolescent, and higher number of lifetime severe/blis-
tering sunburns (all P<0.0001 for meta-analysis). The multivariate-adjusted risk ratio for the highest
quintile versus the lowest quintile of cumulative midrange ultraviolet (UV) flux exposure based on
residential history was 3.29 [95% confidence interval (CI): 2.79, 3.88] in men and 1.99 (95% CI:
1.65, 2.40) in women. In summary, the increase of BCC incidence rate was generally higher in men
than in women, and BCC risk was associated with several phenotypic and exposure factors includ-
ing midrange UV radiation.
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Hypertension, type 2 diabetes, high cholesterol, related medication use and risk of incident
psoriasis in U.S. women
S Wu,1,2 W Li,1,2 J Han1,2,3 and AA Qureshi1,2 1 Department of Dermatology, Brigham and
Women’s Hospital, Harvard Medical School, Boston, MA, 2 Channing Division of Network
Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical
School, Boston, MA and 3 Department of Epidemiology, Harvard School of Public Health,
Boston, MA
We evaluated whether personal history of hypertension, type 2 diabetes (T2D), high cholesterol, or
related medication use is associated with risk of incident psoriasis. A total of 162,051 participants
were included from the Nurses’ Health Study (NHS, 1996-2008) and Nurses’ Health Study II (NHS
II, 1991-2005). Information on personal history of physician-diagnosed hypertension, T2D, high
cholesterol, and related medication use was collected biennially during follow-up. Relative risks
(RRs) of incident psoriasis were estimated using Cox proportional hazards models adjusting for
potential confounders. During 2,238,429 person-years of follow-up, a total of 1,034 incident pso-
riasis cases were confirmed. Hypertension was associated with an elevated risk of psoriasis among
those using anti-hypertensive drugs in the combined analysis [multivariate-adjusted RR =1.32,
95% confidence interval (CI): 1.02, 1.71], and users of beta-blockers were at a higher risk [RR=1.38,
(95%CI: 1.08, 1.75)]. High cholesterol was associated with an elevated risk of psoriasis in the com-
bined analysis [RR=1.26, (95%CI: 1.06, 1.50)]. T2D was not associated with an elevated risk of
psoriasis. In summary, high cholesterol was associated with an elevated risk of incident psoriasis
whereas hypertension was only associated with an elevated risk in the presence of anti-hyperten-
sive medication use.
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Genital psoriasis is associated with significant impairment in quality of life and sexual func-
tioning
C Ryan,1 MN Sadlier,2 M Patel,1 B Kirby2 and A Menter1 1 Dermatology, Baylor University
Medical Center, Dallas, TX and 2 Dermatology, St Vincent’s University Hospital, Dublin,
Ireland
Although genital involvement can have devastating psychosexual implications for psoriasis patients,
few studies have examined predisposing risk factors or its impact on quality of life and sexual func-
tioning. This was an observational, multi-center study of 354 consecutive adult patients with psori-
asis. Information on patient demographics, clinical severity and phenotype, patient quality of life
and sexual functioning was collected. 224 patients (63%) had a current and/or previous history of
genital involvement. Of these patients, 87% reported itch, 39% reported pain, 42% reported dys-
parenia, 32% reported a worsening of their genital psoriasis after intercourse and 43% reported a
decreased frequency of intercourse as a result of their genital involvement. Younger age of onset of
psoriasis (p<0.0001 for type I versus type 2 psoriasis), more severe disease (p<0.0001 for Psoriasis
Area and Severity Index and percentage of body surface area involved), current scalp, nail and flex-
ural involvement were associated with the presence of current genital disease, patients with palmo-
plantar involvement were less likely to have a history of genital involvement (p=0.003), while there
was no association with joint involvement, circumcision, smoking or obesity. There was strong evi-
dence that patients with current genital psoriasis had a severe impairment in quality of life and sex-
ual health as determined by the Dermatology Life Quality Index (p < 0.001), the Center for Epi-
demiologic Studies Depression Scale (p=0.01) and the Relationship and Sexuality Scale (p < 0.001),
which was significant in all categories including frequency, quality and fear of sexual relations. The
results of this study highlight the psychosexual impact of psoriasis and emphasize the need for der-
matologists to systematically screen all psoriasis patients for the presence of genital involvement
and the impact of their disease on sexual health.
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Determinants of survival in dermatofibrosarcoma protuberans patients developing subsequent
primary cancers
DE Kurlander,1 JS Barnholtz-Sloan,1,3 H Gittleman,3 Y Chen,1,3 MR Gerstenblith1,2 and
JS Bordeaux1,2 1 Case Western Reserve University School of Medicine, Cleveland, OH, 2
Department of Dermatology, University Hospitals Case Medical Center, Cleveland, OH and 3
Case Comprehensive Cancer Center, Cleveland, OH
Recently the research team found patients with dermatofibrosarcoma protuberans (DFSP) to be at
increased risk of subsequent primary melanoma, female breast, soft tissue, and other non-epithe-
lial skin cancers, and at decreased risk of colon cancer. This study describes survival of DFSP patients
stratified by subsequent primary cancers. Data from the Surveillance, Epidemiology and End Results
Program’s 9 registries with dates 1973-2009 were used for analysis. Three cohorts were used: Cohort
1, individuals with DFSP and no secondary cancer; Cohort 2, individuals with DFSP with the fol-
lowing secondary cancers: female breast, soft tissue, other non-epithelial skin, colon, and melanoma;
and Cohort 3, individuals with DFSP and any other secondary cancer. Kaplan-Meier survival analy-
ses were performed within each Cohort to assess potential survival differences by age at diagnosis,
sex, race, and primary site of the tumor. Multivariable Cox proportional hazards models were per-
formed to further assess survival differences adjusting for all factors. For all Cohorts, survival decreased
as age at diagnosis increased, in the univariate and multivariate models. For Cohort 1 (N=3459), in
the multivariable model black race, male sex, and tumor location on the lower extremity, head, or
other site were associated with a significantly increased risk of death. For Cohort 2 (N=131), in the
multivariable model black race and tumor location on the genitals were associated with a signifi-
cantly increased risk of death. For Cohort 3 (N=268), in the multivariable model tumor location on
the upper extremity was associated with a significant increased risk of death. Decreased survival
by specific key factors is variable for those with and without secondary cancers after DFSP diag-
nosis. Further analyses will tease out these differences.
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Minimal Clinically Important Difference (MCID) of the Dermatology Life Quality Index (DLQI)
scores and responsiveness to change in inflammatory dermatoses
MK Basra,1 S Salek2 and AY Finlay1 1 Department of Dermatology and Wound Healing, Cardiff
University School of Medicine, Cardiff, United Kingdom and 2 Centre for Socioeconomic
Research, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff,
United Kingdom
The aims of this study were to determine the Minimal Clinically Important Difference (MCID) and
responsiveness to change of the DLQI in inflammatory skin diseases. This was a longitudinal study;
in the first stage patients attending the dermatology out-patient clinic completed the DLQI and a
self-assessed disease severity global question (GQ) on a 0-10 visual analogue scale. At the follow-
up stage patients completed the DLQI, the GQ and a global rating of change questionnaire (GRCQ)
about the change in their overall quality of life (QoL). GRCQ was used as an anchor to measure the
MCID of the DLQI scores with a 15-point scoring system (+7 to -7). A total of 192 patients (M=41.7%,
F=58.3%) with 20 different inflammatory skin diseases completed the DLQI and GQ at stage 1 while
107 patients completed the DLQI, GQ and GRCQ at stage 2 (mean time interval=71 days). The
mean DLQI score of 107 patients at stage 1 was 9.8 (SD=7.8) and 7.4 (SD=7.0) at stage 2 with a
mean change of 2.4 (p<0.0001). The ES was 0.3 while the SRM was 0.4, both indicating a small
effect according to Cohen’s criteria. 31 patients experienced a “small change” in their QoL (±3 and
±2 ) on the GRCQ. The mean corresponding change in DLQI scores was 3.3 (SRM=0.27; ES=0.21)
which could be regarded as the approximate MCID of the DLQI scores. The mean DLQI scores in
patients with “no change”, “moderate” and “large” change on the GRCQ were 2.7 (n=23; SRM=0.01,
ES=0.004), 4.4 (n=25; SRM=0.46, ES=0.39) and 6 (n=28; SRM=0.69, ES=0.67) respectively. These
findings confirm that the DLQI is responsive to change in patients’ QoL over time. Previous esti-
mates of DLQI MCID have varied from 3 to 5: the recommendation from this study is that MCID=3
in inflammatory diseases. This new information is of relevance to the use of the DLQI in clinical
research and practice.
558
Development and validation of teenagers’ Quality of Life (T-QoL©) index: A dermatology-
specific measure for adolescents
MK Basra,1 AY Finlay1 and S Salek2 1 Department of Dermatology and Wound Healing, Cardiff
University School of Medicine, Cardiff, United Kingdom and 2 Centre for Socioeconomic
Research, School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff,
United Kingdom
The aim of this study was to develop and validate a dermatology-specific quality of life instrument
for adolescents with skin diseases. The Classical Test Theory (CTT) and Item Response Theory (IRT)
models were employed to develop this new tool and to conduct its psychometric testing. 33 aspects
of QoL were identified from semi-structured qualitative interviews with 50 adolescents with skin
disease, leading to a 32-item first version of T-QoL. Based on the feedback from 20 adolescents, 2
items were removed resulting in 30-item T-QoL which was then completed by 153 adolescents.
Rasch analysis using RUMM 2030 software did not support the validity of the T-QoL as a unidi-
mensional measure; factor analysis identified 3 domains. Further 12 items were removed based on
Rasch analysis and on CTT, creating the final 18-item questionnaire. Psychometric evaluation was
carried out on a new cohort of 203 adolescents (M=115; F=88, mean age=16.2 years). The con-
struct validity of the tool was demonstrated by correlation with Skindex-Teen (r=0.83, p<0.0001),
the CDLQI (r=0.75, p<0.001), and the DLQI (r=0.74; p<0.0001). T-QoL showed excellent internal
consistency with Cronbach’s alpha α=0.89 for the total scale score and 0.85, 0.60, and 0.74 for the
3 domains. Similarly, the test re-test reliability was high in stable subjects (n=61) after a mean inter-
val of 7.2 days: Intraclass correlation coefficient (ICC)=0.91 for the total scale and 0.9, 0.76 and
0.74 for the 3 domains. There was a significant change in the total scale score in 41 subjects (mean
change=2.46; p=0.02, normal T-QoL score range=0-36) whose skin disease had changed after a
mean of 122.5 days (SD=81.2). Built on rich qualitative data from patients, the T-QoL is a simple
and valid tool to quantify the impact of skin disease on adolescents’ QoL; it could be used as an
outcome measure in both clinical practice and in clinical research.
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Identification of cutaneous T-cell lymphoma geographic hotspots in Houston metropolitan
area
IV Litvinov,1 MT Tetzlaff,2 E Rahme,3 P Gangar,4 M Tetzlaff,2 K Pehr,1 VG Prieto,2 D Sasseville1 and
M Duvic4 1 Dermatology, McGill University Health Centre, Montreal, QC, Canada, 2
Pathology, MD Anderson Cancer Center, Houston, TX, 3 Clinical Epidemiology, McGill
University Health Centre, Montreal, QC, Canada and 4 Dermatology, MD Anderson Cancer
Center, Houston, TX
Cutaneous T-Cell Lymphoma (CTCL) is a rare cancer with documented incidence of ~4-8 cases per
million individuals per year. Currently the pathogenesis of CTCL remains unknown. Previous case
reports suggested that this cancer can occur in married couples as well as cluster geographically
and in families, therefore raising a possibility that there might be an important external cause.
However, to date there are no documented geographic disease hotspots. In the current work we
analyzed the demographic data of 1047 patients from Texas that were seen in a CTCL clinic at the
MD Anderson Cancer Center during 2000-2012. Our findings document geographic clustering of
patients in a number of communities within the Houston metropolitan area. Furthermore, our results
reveal three communities with CTCL incidence rate of 10-50 times higher than the expected rate.
In addition, comparison of the disease rate in these communities to the observed rate of CTCL in
Texas patients visiting our clinic during 2000-2012 suggests a significant raise after ~2006. In con-
clusion, identification of geographic clustering combined with the discovery of CTCL disease hotspots
strongly argues for the existence of yet unknown external cause in triggering this rare cancer. Iden-
tification of additional CTCL hotspots around the world will help identify this trigger and will bring
us closer to eradicating death and suffering from this disease.
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Personal history of psoriasis and the risk of non-melanoma skin cancers
M Chen,1 A Qureshi,1,2 T Li1,2 and J Han1,2,3 1 Dermatology, Brigham and Women’s Hospital and
Harvard Medical School, Boston, MA, 2 Channing Laboratory, Brigham and Women’s
Hospital and Harvard Medical School, Boston, MA and 3 Epidemiology, Harvard School of
Public Health, Boston, MA
Background: Some clinical studies have suggested an increased risk of non-melanoma skin cancers
among psoriatic patients. However, no large cohort studies have been conducted on personal his-
tory of psoriasis and the risk of non-melanoma skin cancers. Objectives: We investigated the asso-
ciation between personal history of psoriasis and the risk of incident non-melanoma skin cancers
in a mixed retrospective–prospective cohort design. Methods: We obtained data from three large
population-based cohort studies in U.S. women and men. All enrolled participants were followed
up to 2008. In a total of 188,406 participants, we identified 3,216 individuals with psoriasis. We
calculated relative risks (RRs) and 95% confidence intervals (CIs) of developing non-melanoma
skin cancers using logistic regression models. Results: We documented 3,276 incident SCC cases
and 19,300 incident BCC cases. Psoriatic patients had a multivariate-adjusted RR of 1.40 (95%CI,
1.09-1.79) for SCC compared with those without psoriasis. The individuals with severe psoriasis
are more likely to develop SCC (RR, 1.26 for 3 or more palms of psoriasis; 95%CI, 1.06-1.50; p for
trend, 0.01). However, personal history of psoriasis was not associated with the risk of BCC (RR,
1.00; 95%CI, 0.88-1.13). Conclusions: We found that personal history of psoriasis was significantly
associated with an increased risk of SCC, but not BCC. Psoriasis may share some common immune
pathogenesis with SCC. Certain therapeutic regimens for psoriasis perhaps increase the risk of SCC.
Key words: psoriasis, non-melanoma skin cancer.
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Severe teenage acne and breast cancer risk
M Zhang,1 AA Qureshi,1,2 RT Fortner,2 SE Hankinson,2,3 Q Wei,4 L Wang,4 H Eliassen,2,5
WC Willett,2,5,6 DJ Hunter2,5,6 and J Han1,2,5 1 Dermatology, Brigham and Women’s Hospital,
Boston, MA, 2 Medicine, Brigham and Women’s Hospital, Boston, MA, 3 Public Health,
University of Massachusetts Amherst, Amherst, MA, 4 Epidemiology, The University of Texas
M.D. Anderson Cancer Center, Houston, TX, 5 Epidemiology, Harvard School of Public
Health, Boston, MA and 6 Nutrition, Harvard School of Public Health, Boston, MA
Background: Acne has been suspected as a result of high levels of circulating androgens, which may
increase the risk of breast cancer. We aimed to investigate whether a history of severe teenage acne
may predict subsequent risk for breast cancer in our prospective cohort. Methods: We followed
99,128 female nurses for 20 years (1989-2009) in the large well-characterized Nurses’ Health Study
II cohort. We used Cox proportional hazards models to estimate the relative risks of breast cancer
for women with severe teenage acne. We additionally compared the mid-life plasma androgen lev-
els between women with and without a history of teenage acne (n=2,269). Results: During follow-
up, 3,303 breast cancer cases were diagnosed. Among women with a history of severe teenage acne,
the relative risk was significantly increased for breast cancer (multivariable-adjusted relative risk,
1.17; 95%CI, 1.03-1.32). We confirmed that women with a history of severe teenage acne had
higher mid-life free testosterone levels compared to those without (0.17 vs. 0.15 ng/dL, P=0.02).
Conclusion: Our results suggest a history of severe teenage acne is a novel risk factor for breast
cancer independent from previously identified risk factors. Elevated androgens may contribute eti-
ologically to the observed associations.
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Use of tanning beds and total cancer risk
M Zhang,1 F Song,2 DJ Hunter,3,4,5 AA Qureshi1,3 and J Han1,3,5 1 Dermatology, Brigham and
Women’s Hospital, Boston, MA, 2 Epidemiology, Tianjin Medical University Cancer Institute
and Hospital, Tianjin, China, 3 Medicine, Brigham and Women’s Hospital, Boston, MA, 4
Nutrition, Harvard School of Public Health, Boston, MA and 5 Epidemiology, Harvard School
of Public Health, Boston, MA
Purpose: To investigate the potential health benefits of indoor tanning regarding prevention of inter-
nal cancers in the same cohort where we observed increased risks of skin cancers among tanning
bed users with a dose-response relationship. Patients and methods: We follow 73,358 female nurses
for 20 years (1989-2009) in the Nurses’ Health Study II and investigated the frequency of tanning
bed use during high school/college and at ages 25-35 in relation to the incidence of total cancers
(excluding skin cancers). We used multivariate Cox proportional hazards models to estimate the rel-
ative risks (RRs) and 95% confidence intervals (CIs) of total cancers and each individual major can-
cer with more than 100 cases. Results: During follow-up, a total of 4,271 internal cancer cases
were diagnosed. No association was found between tanning bed use and risk of total cancers (mul-
tivariable-adjusted RR, 0.99; 95% CI, 0.95-1.04 for every 4 times/year use on average during high
school/college and at ages 25-35). In addition, no association was found for the risk of any indi-
vidual major cancers, such as breast cancer, thyroid cancer, colorectal cancer, non-Hodgkin lym-
phoma, or endometrial cancer. Conclusion: Our data do not suggest any association between the
use of tanning beds and risk of internal cancers. The presumed short-term elevation of plasma vita-
min D levels produced by the use of tanning beds does not necessarily translate into risk reduction
for internal cancers.
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The role of evidence based dermatology in World Health Organization guidelines
EE Freeman,1 P Easterbrook,2 L Muhe,3 R Hay,4 J Martin5 and T Maurer6 1 Dermatology,
Massachusetts General Hospital, Boston, MA, 2 HIV Department, World Health Organization,
Geneva, Switzerland, 3 Department of Child and Adolescent Health and Development, World
Health Organization, Geneva, Switzerland, 4 International Foundation for Dermatology,
London, United Kingdom, 5 Department of Epidemiology and Biostatistics, University of
California, San Francisco, CA and 6 Dermatology, University of California, San Francisco, CA
The World Health Organization (WHO) is in the process of developing HIV Dermatology Guide-
lines for the first time. A total of 52 HIV-associated dermatologic conditions were assessed for pos-
sible inclusion in the guidelines. Inclusion was based on high burden of disease in HIV-infected
adults and children, severity of disease or risk of progression, impact on prognosis of HIV, condi-
tions leading to antiretroviral therapy initiation, availability of evidence, applicability for primary
health care in resource poor settings, availability of effective interventions, and lack of guidance in
currently available guidelines for resource poor settings. A total of 11 cutaneous and 2 oral condi-
tions were selected for potential inclusion. As per WHO protocol, a review was then undertaken of
each of these conditions to identify high quality systematic reviews with or without meta-analyses
from in the past three years. Data gaps, with lack of up-to-date high quality systematic reviews for
HIV patients, were identified for Kaposi’s sarcoma, photodermatoses, crusted scabies, eosinophilic
folliculitis, papular pruritic eruption, HIV-associated drug reactions, drug resistant HSV, and necro-
tizing gingivitis. Systematic reviews are being performed to address these identified gaps. The
WHO HIV Dermatology guideline process highlights the increasing role of systematic review, meta-
analysis, and evidence based decision making in Dermatology. It also underscores the importance
of these epidemiologic tools in raising the profile of Dermatologic disease on the world stage.
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The need for unified international guidance on HIV dermatology
EE Freeman,1 R Evans,2 T Maurer,4 L Muhe3 and P Easterbrook2 1 Dermatology, Massachusetts
General Hospital, Boston, MA, 2 HIV Department, World Health Organization, Geneva,
Switzerland, 3 Child and Adolescent Health, World Health Organization, Geneva,
Switzerland and 4 Dermatology, University of California, San Francisco, CA
In the developing world, an area with few practicing Dermatologists, clear guidance is needed on
the treatment of HIV-associated skin conditions. In an effort to summarize current national and inter-
national guidelines covering HIV Dermatology, a search was undertaken of governmental and pro-
fessional society guidelines worldwide. Potentially relevant guidelines for HIV-related skin condi-
tions were identified from over fifteen different organizations and national governing bodies, resulting
in over forty potentially relevant guidelines published since 1996. For HIV patients, these guide-
lines addressed adverse HIV-drug reactions, atopic dermatitis, syphilis, HSV, zoster, candidiasis,
immune reconstitution inflammatory syndrome, leishmaniasis, HPV, papular pruritic eruption, pho-
toaggrevated dermatoses, impetigo, tinea, warts, molluscum, Kaposi’s sarcoma, scabies, eosinophilic
folliculitis, and cutaneous tuberculosis. A wide range of decision-making paradigms were employed
in the development of these guidelines, ranging from expert opinion to more formalized evidence-
based practices such as the Grading of Recommendations Assessment Development and Evalua-
tion (GRADE) process employed by the World Health Organization. Only two guidelines were iden-
tified that summarized HIV-associated dermatologic conditions and these were both published in
the 1990s. The remaining guidelines were limited in their scope in that they a) were developed for
HIV opportunistic infections in general and thereby included some dermatology, b) addressed sex-
ually transmitted infections in general or c) only addressed a very few disease entities. This review
identified a gap in up-to-date, evidence based guidelines for HIV Dermatology as a field. The
World Health Organization is currently in the process of developing HIV Dermatology guidelines
in order to fill this void and provide much needed guidance to those working on the front lines of
HIV care.
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Association between severe acne in adolescence and sinopulmonary and gastrointestinal
comorbidity: A US population-based study
JI Silverberg and NB Silverberg Dermatology, St. Luke’s-Roosevelt Hospital and Beth Israel
Medical Center, New York, NY
Little is known about the epidemiology of severe acne in the US. We sought to study the US preva-
lence, determinants and comorbidities of severe acne in childhood. We analyzed the 2007 National
Health Interview Survey from 9,417 children ages 0-17 years. The US prevalence of severe acne
was virtually nil in the first decade of life, but increased in a linear fashion from 11 years (1.7%
[CI95]: 0.4–3.0%]) to 17 years of age (12.1% [7.8–12.5%]) (Rao-Scott Chi-square, P<0.0001). Severe
acne was more common in Whites compared with other racial groups at age 14-15 years (P=0.0004)
and girls at age 11-13 (P=0.02). Severe acne was associated with increased problems being over-
weight (multivariate logistic regression, P<0.0001) and comorbid disease. Sinopulmonary disease
included sinus infection (P=0.0003), sore throat not due to Strep infection (P=0.0003), asthma
(P=0.03), other non-asthmatic lung disease (P=0.03), but not Strep throat/tonsillitis (P=0.07), hay
fever (P=0.04) or respiratory allergy (P=0.06). Upper gastrointestinal comorbidities included
reflux/heartburn (P=0.0003), abdominal pain (P=0.03), nausea/vomiting (P=0.0001) and food/diges-
tive allergy (P=0.01), but not frequent diarrhea/colitis (P=0.56) or recurring constipation (P=0.09).
Psychological comorbidities included depression (P=0.02), anxiety (P<0.0001), attention deficit dis-
order/attention deficit hyperactivity disorder (P=0.01) and insomnia (P=0.02), but not phobias
(P=0.77). In conclusion, there is a significant association between the US prevalence of severe acne,
overweight, sinopulmonary, upper gastrointestinal and psychological diseases in children. This
suggests that acne may share a common pathogenesis with these disorders.
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Common warts in childhood are associated with increased atopy and infections: A US pop-
ulation-based study
JI Silverberg and NB Silverberg Dermatology, St. Luke’s-Roosevelt Hospital and Beth Israel
Medical Centers, New York, NY
Little is known about the epidemiology of common warts in the US. We sought to study the US
prevalence of warts in childhood and its determinants. We analyzed the 2007 National Health Inter-
view Survey, a cross-sectional study of 9,417 children ages 0-17 years sponsored by the National
Center for Health Statistics. Prevalence of warts, demographics, atopic and other infectious dis-
eases were determined. Overall, the US prevalence of childhood warts was 3.3% [95% confidence
interval (CI95): 2.8–3.8%]. The prevalence of warts steadily increased between 1-2 and 7-8 years
of age, peaked at 9-10 years (8.6% [6.2–11.1%] and then plateaud at 11-17 years (Rao-Scott Chi-
square, P<0.0001). Warts were most common in Whites (P<0.0001), non-Hispanics (P<0.0001) and
in households with greater income (P=0.002), higher level of education (P=0.0009) and both par-
ents present (P=0.02). Warts were associated with eczema (logistic regression; P=0.03), hay fever
(P<0.0001) and respiratory allergy (P<0.0001), but not asthma or food allergy (P≥0.36). Warts were
associated with recent history of Strep throat (P<0.0001), other sore throat (P<0.0001), influenza
(P=0.004) and sinus infections (P<0.0001) but not recurrent ear infections (P=0.28). These associ-
ations remained significant in multivariate models that controlled for age, Race, ethnicity, house-
hold income and highest level of education. In summary, there is a significant association between
the US prevalence of warts, atopic and other infectious diseases in children. This suggests that bar-
rier and/or immune disruption contributes toward the pathogenesis of warts.
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The prevalence of alopecia areata among 915,429 dermatology patients seen in dermatology
private practice offices throughout the United States
JA Solomon,1,2 D Chever1 and C Caldwell2 1 Ameriderm Research, Ormond Beach, FL and 2
University of Central Florida College of Medicine, Lake Nona, FL
The prevalence of alopecia areata (AA) patients being seen at dermatology practices throughout the
United States (US) is unclear. Albeit several reviews have been published, no large review of the
prevalence of US patients with AA has been conducted. The largest review of patients published is
a Japanese study involving 67,444 patients at 170 clinics. Leavitt Medical Associates of Florida oper-
ates or manages 353 dermatology offices involving 915,429 patients seen throughout the US. We
undertook a nationwide review to evaluate the prevalence of patients with a diagnosis of AA (ICD-
9 code 704.01) presenting to this group of dermatology offices. Corporate billing data was col-
lected in regard to age, gender and diagnosis. Of the 915,429 patients, 82,732 were diagnosed
with a hair loss ICD-9 code (091.82, 306.3, 697.0, 704.0 704.00, 704.1, 704.2, 704.8, 757.39,
757.4). Of these, a total of 6,621 patients were diagnosed with AA; equal to 0.7 % of all patients
seen, 8 % of patients seen with any hair disorder. Patients with AA ranged from 1 to 98 years of age
(yo). Both males (m) and females (f) were distributed over a Gaussian distribution. Nevertheless,
males peaked in the 30-39 yo, while females peaked later at 40-49 yo. Of patients 0-10 yo who
presented with any type of hair loss, the prevalence of AA was 20.9% m 19.7% f 21.9% . For 31-
40 yo 17.9%, m 22.1%; f 15.1%; for 50-59 yo 18.4%, m 13.1% f 21.5%. From these data one can-
not determine whether or not the earlier peaking of the male is related to disease incidence or to
the decreasing concern among older males with hair loss. AA clearly represents a significant com-
ponent of patients presenting with hair loss to US dermatology offices with the prevalence varying
by age and sex.
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Risk of subsequent cutaneous squamous cell carcinoma in patients with melanoma
MM Asgari,1 E Warton,1 C Quesenberry,1 D Koralek2 and M Taylor2 1 Kaiser Permanente
Northern California, Oakland, CA and 2 Epidemiology and Patient Reported Outcomes,
Genentech, South San Francisco, CA
Melanoma patients are at increased risk of cutaneous squamous cell carcinoma (cSCC), yet the
impact of demographic and tumor-related variables on cSCC risk has not been systemically exam-
ined. Using a consecutive cohort of melanoma patients diagnosed in a large integrated healthcare
delivery system, we examined the incidence rate of cSCC and determined the impact of patient
characteristics (age, gender, race/ethnicity) and melanoma tumor characteristics (sequence number,
anatomic site, size, stage, and histologic subtype) on cSCC risk. We identified all members of
Kaiser Permanente of Northern California (KPNC) diagnosed with a melanoma from 2000-2005
(n= 6,378) and obtained data on patient and tumor characteristics and outcomes (cSCC, mortality)
from KPNC electronic databases. We calculated incidence rates assuming the Poisson distribution
for event counts. Cox proportional hazard models were used to estimate crude and adjusted haz-
ard ratios. A total of 766 subjects developed cSCCs after their initial melanoma diagnosis during
follow-up. The median time to cSCC was 2.12 years (mean 2.66, SD 2.22). The overall cSCC crude
incidence rate was 2.41 per 100 person-years, and was higher among males (3.10, 95% CI 2.84-
3.37) and older subjects. In adjusted models, risk of cSCC was higher among males (HR 1.60, 95%
CI 1.37-1.87), older subjects (HR 13.33, 95% CI 8.99-19.77 in subjects >80 compared to <50 years),
and non-Hispanic whites (HR 3.30, 95% CI 1.47-7.40). Melanoma characteristics, such as sequence
number (HR 1.69, 95% CI 1.26-2.25 comparing 1 to > 3) and anatomic site (HR 1.19, 95% CI
1.01-1.39 sun-protected to sun-exposed) were also associated with cSCC risk. Sensitivity analyses
adjusting for outcome definition and cohort entry criteria did not affect our results. In summary,
melanoma survivors are at high risk for subsequent cSCC and should be screened with full-body
skin check at regular intervals not only for melanoma surveillance, but also for cSCC detection.
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Atrial fibrillation and electrocardiographic characteristics among patients with psoriasis and
coronary heart disease
AW Armstrong,1 S Azizi,2 J Wu,1 C Harskamp,1 J Farrow,2 K Klem,2 D Anderson2 and EJ Armstrong2
1 Dermatology, University of California Davis, Sacramento, CA and 2 Cardiovascular
Medicine, University of California Davis, Sacramento, CA
Psoriasis patients have an increased incidence of cardiovascular disease. Atrial fibrillation is the
most common cardiac arrhythmia and is associated with increased morbidity and risk of stroke.
The objective of this study is to assess the association between psoriasis and incident atrial fibrilla-
tion. Patients with psoriasis who underwent cardiac catheterization were matched to patients with-
out psoriasis at University of California. Electrocardiograms of all subjects were reviewed. The Fram-
ingham risk score for atrial fibrillation was calculated to predict incident atrial fibrillation. The
subsequent incidence of atrial fibrillation was assessed by chart review with electrocardiographic
confirmation. From the 9,473 patients who underwent coronary angiography, 169 patients with pso-
riasis and no prior atrial fibrillation were identified. When compared to matched controls, psoria-
sis patients had a higher body mass index (31.5 vs. 29.6 kg/m2, P=0.008), but were less likely to
have a history of heart failure or hypertension. Patients with psoriasis had a trend towards a decreased
predicted incidence of atrial fibrillation (12.8% vs.14.6% over a ten year period, P=0.06). During
a median follow-up of 2.5 years, the observed incidence of atrial fibrillation was similar between
cases and controls (Hazard Ratio 0.9, 95% CI 0.5-1.8, P=0.8). Patients with moderate-to-severe pso-
riasis had a trend towards an increased incidence of atrial fibrillation during follow-up, with a haz-
ard ratio of 2.0 (95% CI 0.5-7.8, P=0.3). Moderate to severe psoriasis may be associated with an
increased incidence of atrial fibrillation. Larger studies are needed to confirm this finding.
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Diet and stress perceived to make acne worse in UK teenagers
K Bhate, HC Williams and M Ozolins Centre of Evidence Based Dermatology, University of
Nottingham, Nottingham, United Kingdom
Although acne is almost universal amongst adolescents, little is known about their beliefs about
which factors that may cause the disease to worsen. We sought to describe the perceptions of a
cohort of adolescents with acne about which factors made their acne worse. Adolescents with mild
to moderate facial acne taking part in a large clinical trial of commonly used acne treatments in the
community were asked the question ‘is there anything that makes your acne worse?’. Those respond-
ing positively were then asked to elaborate on their perceptions of what worsened their acne using
unlimited free text in a study questionnaire. Of the 649 adolescents who took part in the trial, 367
(57%) replied to the question on factors worsening acne, which in turn resulted in 489 itemised
responses listing various perceived exacerbating factors including: stress (18.6%), diet (15.1%), facial
washes and gels, over the counter (OTC) products (8.8%), menstruation (6.3%) and sweating (6.3%).
The most frequent dietary factors perceived to worsen acne were chocolate (3.3%), alcohol (2.7%)
and greasy foods (2.7%). This secondary data analysis illustrates the range of factors that adoles-
cents believe can worsen their acne. Stress and dietary components were the factors perceived to
worsen acne most commonly in this study. The use of face washes and winter time or cold weather
are not commonly cited reasons found in other studies and are worth further investigation. Knowl-
edge of such beliefs helps to identify items that need to be covered in a consultation with a young
person with acne so that genuine factors can be explored and myths dispelled. The findings also
underline the need to research some of the factors such as diet, stress, sweating, cold weather and
wash products more rigorously through epidemiological studies and well designed randomised
provocation or prevention studies.
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Epidemiological and clinical characteristics of Behçet’s disease in Korea - using a clinical data-
base for patients’ registry
S Na,1 D Kim,2 M Cho,2 D Bang,2 J Roh,3 S Lee1 and E Lee4 1 Dermatology, Ajou University,
Suwon, Republic of Korea, 2 Dermatology, Yonsei University, Seoul, Republic of Korea, 3
Dermatology, Gachon University Gil Medical Center, Incheon, Republic of Korea and 4
Rheumatology, Chonnam National University, Kwangju, Republic of Korea
Behçet’s disease is a multisystemic inflammatory disorder which shows geographic predominance,
specifically in the Far East, such as Korea, China and Japan. This study was planned to establish
prospective epidemiologic data of Korean patients as well as diagnostic and therapeutic guidelines
through an expert network. On the basis of literature review and analysis, we concluded that fur-
ther investigation on aggravating factors of Behçet’s disease is necessary and other objective scor-
ing systems need to be developed, as subjective indices reported by the individual patient are often
exaggerated. Based on the results from the first preliminary registration, we have amended the
research protocol and added aggravating factors of the disease. Overall, 36 patients with Behcet’s
disease mainly from 4 hospitals were prospectively enrolled in the revised protocol. The patients
were classified according to the International Study Group (ISG) criteria and revised Japanese clas-
sification based on their medical records. The sex ratio was 1:2.6 with female predominance. The
incidence among the subgroups was incomplete type 97.2%, complete type 2.8%. Interestingly, 8
people who satisfied Japanese classification did not satisfy the ISG criteria. Clinically, 100% had
oral ulcers, 75.0% had genital ulcers, 77.8% had skin lesions and 25.0% had ocular lesions. As for
the minor clinical manifestations, joint symptoms were the most frequent. The pathergy test was
positive in only 9.7% of the patients. Our final aim is to understand the clinical characteristics, nat-
ural history and prognostic factors of Korean BD patients through patients’ registry for early detec-
tion and proper treatment of BD patients.
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Journal of the American Academy of Dermatology facebook page posting metrics
R Dellavalle1,2 and R Gamble1 1 Dermatology, University of Colorado School of Medicine,
Aurora, CO and 2 Dermatology, Veterans Affairs Medical Center, Denver, CO
We analyzed user demographic and posting popularity data for the Journal of the American Acad-
emy of Dermatology (JAAD) Facebook page on 12/20/2012 to investigate factors promoting audi-
ence engagement. The top 5 posts (users reached) with the largest reach were: Heparin reaction!
(NEJM Images Physicians should know) (1363), Basal cell carcinoma associated with eczema (1330),
Median rhomboid glossitis (NEJM Images in Clinical Medicine) (1,324), Lingual Zoster (NEJM Images
in Clinical Medicine (1,272), Secondary syphilis (NEJM Images Physicians should know) (1267). The
top 5 posts (users engaged) with most engaged users were: Tinea (NEJM Images in Clinical Medi-
cine) (212), Median rhomboid glossitis (NEJM Images in Clinical Medicine) (209), Lingual Zoster
(NEJM Images in Clinical Medicine (193), Podoconiosis (NEJM Images in Clinical Medicine) (169),
Secondary syphilis (NEJM Images Physicians should know) (166). The top 5 posts (date posted;
users talking) talked about were: Scientists discover children’s cells living in mother’s brains (122),
Are you eating enough chocolate? (63), Coffee consumption correlates with less BCC! (61), Tattoo
ink infections! (47), J&J removing carcinogens from products (44). Users who “liked” the page were
65% female, with an age distribution of 18-24 years old: 11%, 25-34 years old: 52%, 35-44 years
old: 22%, 45-54 years old: 9%, 55+ years old: 4%. The top countries of origin were United States
(21%), Brazil (17%) and Egypt (13%). The top languages based on default language settings were
English (60%), Portuguese (16%) and Spanish (6%). Links containing clinical case photographs,
those related to skin cancer prevention, and correlative studies were well represented among the
top posts. Also, the demographics of users that “liked” JAAD’s page continue to show an interna-
tional range of users.
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An instrument for measuring skin aging in large-scale epidemiological studies holds promise
as a monitor for general aging or disease processes
A Vierkötter, L Effner, B Hoffmann, U Krämer and J Krutmann IUF-Leibniz Research Institute for
Environmental Medicine, Düsseldorf, Germany
We hypothesize that facial aging reveals dysfunction or disease of internal organs. A previous report,
for example, found an association between facial wrinkling and airflow obstruction. The aim of our
study was to establish a fast and non-invasive skin aging measurement instrument for large-scale
epidemiological studies to investigate the association of skin aging and general aging or disease
processes. We tested two different skin aging evaluation instruments in 182 subjects: (1) a skin aging
score (SCINEXA) and (2) a digital Imaging system (VISIA, Canfield Scientific Inc, USA). By SCINEXA,
investigators visually evaluated the severity of skin aging signs like wrinkles and spots. VISIA meas-
ures wrinkles and spots quantitatively from photographs. The practicability of the 2 instruments was
evaluated according to training effort, inter- and intra-investigator variability, acceptability by
investigators and study subjects and costs. The scientific relevance was evaluated by the associa-
tion of skin aging with chronological age and airflow obstruction (Pearson correlation). Both instru-
ments needed a medium training effort of 2 days, inter-investigator agreement was acceptable for
SCINEXA as a deviation of more than 1 score point occurred in only 3% of all evaluations but was
not acceptable for VISIA as standard deviations were too high for all evaluated signs except wrin-
kles. The intra-investigator variability was acceptable for SCINEXA (no deviation of more than 1
score point) but not acceptable for VISIA (standard deviations too high except for wrinkles). Both
instruments had a high investigator/ subject acceptability, both have short subject assessment times,
SCINEXA is much cheaper than VISIA and finally, SCINEXA showed significant associations with
age (p<0.0001) and airflow obstruction (p=0.002) and VISIA only with age (p<0.0001). In conclu-
sion, we would recommend SCINEXA as a suitable skin aging evaluation instrument.
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How to retrieve acceptable scores from DLQI: An introduction to Rasch measurement using
the DLQI in a sample of hand eczema patients
RF Ofenloch,1 TL Diepgen,1 P Elsner,2 E Weisshaar1 and C Apfelbacher3 1 Clinical Social
Medicine, University Hospital Heidelberg, Heidelberg, Germany, 2 Department of
Dermatology, University Hospital Jena, Jena, Germany and 3 Medical Sociology, Institute of
Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany
The dermatology life quality index (DLQI) is the most commonly used dermatology-specific health-
related quality of life (HRQOL) measure. In recent years the psychometric properties of the DLQI
have been a subject of debate as principles of modern test theory seem to be violated. It has been
concluded that the use of the DLQI in psoriasis and atopic dermatitis patients cannot be recom-
mended anymore. The aim of this study was to test whether those violations also occur in patients
with hand eczema. We collected data of 602 hand eczema patients who participated in an inpa-
tient dermatology rehabilitation program in Germany. In order to report meaningful scores of the
DLQI, data was analyzed according to the principles of Rasch measurement, including threshold
order, fit statistics and differential item functioning (DIF) which was used to assess the impact of cen-
tre, gender and age. We found 8 items showing DIF and 2 items with disordered thresholds. Over-
all the DLQI showed significant misfit to the Rasch model (p<0.001). We successfully calibrated
the DLQI according to the Rasch model by applying a general algorithm. Items were rescored or
removed from the scale resulting in a 6 item version with a range from 0-15 points. This version
showed no significant misfit to the Rasch model (p>0.14). The results were replicated in another
sample of hand eczema patients (n=511). We conclude that the use of the DLQI to assess HROQL
in hand eczema patients cannot be recommended anymore. If done already the alternative scoring
procedure as presented in this work is recommended for analyzing data. Researchers using the DLQI
in other skin diseases should test the fit of their data according to the principles of modern test and
calibrate the DLQI before reporting results in case of misfit.
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Dynamics of the incidence of cutaneous T- cell lymphomas in Moscow
N Potekaev,1,2 I Khamaganova,1 A Almazova,2 G Lebedeva,2 V Lysenko2 and O Shvec2 1 depart-
ment of skin diseases&cosmetology, Russian national research medical university named after
N.I. Pirogov, Moscow, Russian Federation and 2 Moscow research & practical centre for der-
matology & cosmetology, Moscow, Russian Federation
Cutaneous T- cell lympomas(CTCL) are the most common primary skin lympomas. They are char-
acterized by clonal proliferation of malignant CD 4+ skin-homing lymphocytes. The most common
subtypes are mycosis fungoides and Sézary syndrome. The incidence rate is discussed. Objective
of the study was to assess the incidence of CTCL in Moscow for the last four years. Methods: cal-
culation & statistical manipulation .Results: the total amount of skin diseases was 300540 includ-
ing 47 cases of CTCL in 2008;322323 including 52 cases of CTCL in 2009;354264 including 33
cases of CTCL in 2010;503068 including 17 cases of CTCL in 2011.There was revealed the ten-
dency to decrease the incidence of CTCL (p= 0,06).However, we can not propose the real decline
of the incidence of CTCL.It is well known that the early lesion in CTCL resembles both clinical &
histological benign inflammatory disorders with hyperproliferative epidermis with infiltration of T-
cells & some cases might be misdiagnosed. On the other hand, there is no evidence of the decrease
of the influence of the provocative agents(viral infections, immunosuppressive therapy etc.)on the
the development of CTCL. We did not reveal any reliable changes in examining the incidence of
Kaposi’s sarcoma(KS), which is known to have some predisposing factors similar to those in CTCL.
KS was diagnosed in 22 cases in 2008,in 29 in 2009,in 28 in 2010,in 19 in 2011. The present study
shows that it is necessary to continue the study of the incidence of CTCL.
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High incidence of striae distensae in pediatric adolescent patients on high dose corticos-
teroids for treatment of rheumatic disease and effect on adherence to prescribed regimen
NT Washington1 and AS Chang2 1 Department of Pediatric Rheumatology, Lucile Packard
Children’s Hospital at Stanford University, Palo Alto, CA and 2 Department of Dermatology,
Stanford University Hospitals and Clinics, Palo Alto, CA
The appearance of striae distensae (SD) in adolescent patients within the first three months of high
dose corticosteroid treatment for rheumatic illness has not been reported. Furthermore, the effect
of these scarring lesions on medication adherence is unclear and could have significant conse-
quences if non-adherence resulted in life-threatening organ damage. The purpose of this prospec-
tive observational study is to assess whether the development of SD during high dose steroid ther-
apy affects drug adherence in pediatric rheumatic diseases. After institutional review board approval,
we enrolled participants aged 10-21 years at onset or flare of a systemic autoimmune disease. Sub-
jects underwent treatment with high dose corticosteroids (1-2mg/kg/day) and were assessed monthly
for the development of SD in the axilla, breast, arm, abdomen, back, hip/buttocks, thigh, knee, and
calf. SD were scored by the treating physician for severity and participants completed the Medica-
tion Adherence Self Report Inventory (MASRI), a validated patient adherence tool. A high rate of SD
developed within the first 3 months of high dose steroid treatment (8 out of 11 participants, 72%).
Most frequent sites of SD development were: abdomen (55%), back (55%), and thighs (55%). 80%
of participants reported embarrassment, self-consciousness or sadness due to SD; 40% reported
pain, soreness or pruritus with SD. One of 11 participants who developed SD reported less than
complete adherence. Additional studies with larger sample sizes will shed light on the effect of SD
development and adherence to high dose corticosteroid regimen during the initial, and most cru-
cial time of patients’ diagnoses.
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Trends in social media use among dermatology journals
R Gamble,1 B Gilchrest2 and R Dellavalle1,3 1 Dermatology, University of Colorado, Aurora,
CO, 2 Dermatology, Boston University, Boston, MA and 3 Dermatology, Veterans Affairs
Medical Center, Denver, CO
In order to track the role of social media in medical information transfer, we analyzed postings on
Facebook and Twitter sites for 102 dermatology journals on 5/30/12 and again 6 months later for
the 10 most frequently posted journals. Facebook likes increased by 1,866 (53%) with up to 3007
for the most popular (JAAD) and included the first (JID) and third (JAAD) highest ISI impact factor
journals. Most liked journals (no. Facebook likes 5/30/2012 vs. 1/1/13, ISI Impact Factor), were: 1.
J Am Acad Derm (1747 vs. 3007 likes, 4.0), 2. Arch Derm (716 vs. 972 likes, 3.9), 3. J Clin & Exper
Derm Res (589 vs. 796 likes, 1.1 unofficial), 4. J Derm Nurse Assoc (266 vs. 369 likes, n/a), 5. Cutis
(172 vs. 212 likes, 0.5). Tweets were similar in absolute numbers and increases over 6 months but
3 of the 5 most active accounts were for non ISI-ranked publications. Dermatology journals and
news services (no. Twitter followers 5/13/12 vs. 1/1/13, ISI Impact Factor) tweeting were: 1. Derm
Times (3069 vs. 4272 followers, n/a), 2. Arch Derm (2,283 vs. 3007 followers, 3.9), 3. Derm Online
J (1488 vs. 1890 followers, n/a), 4. Cosmet Derm (393 vs. 716 followers, n/a), 5. J Derm Nurse Assoc
(343 vs. 1749 followers, USA, n/a). About 10% of dermatology journals actively post on Facebook
or Twitter, and 80% of these are US-based compared to 15% of all SCImago dermatology journals.
JID (+1615) and J Derm Nurse Assoc (+1406) had the greatest absolute increases on Facebook and
Twitter respectively. Dermatology journals on Facebook on average had about twice the impact
factor of those tweeting (ISI 1.9 vs 1.0). The data suggest modest but increasing use of social media
among readers of medical journals, with Facebook use predominating among the higher-ranked.
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Ethnic and racial disparities in the use of office-based dermatology visits among the insured,
2005-2010
VM Harvey,1,2 J Paul,3 V Beresovsky4 and L Boulware5 1 EVMS, Norfolk, VA, 2 Hampton
University, Hampton, VA, 3 Virginia Clinical Research, Norfolk, VA, 4 NCHS, Hyatsville, MD
and 5 JHU Bloomberg School of Public Health, Baltimore, MD
Objective:Using data from the National Ambulatory Medical Care Survey, we explored ethnic and
race differences in the utilization of insured office-based dermatology visits in the US. Methods: In
weighted multivariable models providing national estimates, we explored trends in the magnitude
of ethnic/race disparities in dermatology visits and referrals among patients with public and private
insurance from 2005-2010. Results:190,612,400 visits occurred among those with public (Medic-
aid/Medicare or Medicaid/State Children’s Health Insurance Plan) or private insurance.The pro-
portion of dermatology visits attended by minorities remained largely unchanged overall,but increased
among privately insured Hispanics (from 1.3% in 2005 to 4.8% in 2010, p trend=0.003). Individ-
uals with public insurance were statistically significantly less likely to visit dermatologists compared
to those with private insurance (odds ratio (OR) [95% Confidence Interval (CI)]) 0.46 [0.39-0.55]).
Privately insured non-Hispanic Blacks (NHB) and Hispanics had significantly lower odds of attend-
ing visits compared to privately insured non-Hispanic Whites (NHW) (OR [95% CI] 0.61 [0.39-
0.94] and 0.47 [0.35-0.62] for NHB and Hispanics, respectively). NHB and Hispanics with public
insurance also had lower odds of attending dermatology visits compared to NHW (OR [95% CI]
0.38 [0.24-0.62] and 0.45 [0.26-0.80] for NHB and Hispanics, respectively). Referred visits occurred
at equal rates among minorities compared to non minorities, while non-referred visits were statis-
tically significantly less likely to occur among minorities regardless of insurance type.Conclu-
sion:Insured minorities attended dermatology visits less frequently than their non-minority coun-
terparts; disparities were primarily confined within non-referred visits suggesting that system-related
(scarce workforce) and patient related (preferences) factors contribute to disparities in the use of der-
matologic services.
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Risk factors and genetics of sagging eyelids in Europeans
LC Jacobs,1 F Liu,2 I Bleyen,3 DA Gunn,4 A Hofman,5 CC Klaver,3,5 AG Uitterlinden,5 TD Spector,6
M Kayser2 and T Nijsten1 1 Dermatology, Erasmus MC, Rotterdam, Netherlands, 2 Forensic
Molecular Biology, Erasmus MC, Rotterdam, Netherlands, 3 Ophthalmology, Erasmus MC,
Rotterdam, Netherlands, 4 Unilever Discover, Sharnbrook, United Kingdom, 5 Epidemiology,
Erasmus MC, Rotterdam, Netherlands and 6 Twin Research and Genetic Epidemiology, King’s
College, Londen, United Kingdom
Sagging eyelids are a frequent cosmetic concern in the elderly, while risk factors are largely unknown.
Sagging eyelid skin shows the same features as normal aged skin, suggesting a shared aetiology. In
this study we investigate the contribution of exposure to environmental influences and the genetic
predisposition towards developing sagging eyelids. Sagging status was graded for 5,578 Dutch Euro-
peans using digital eye photographs (mean age 67 years, N case = 993) and for 2,186 UK twins
using digital portrait photographs (mean age 53 years, N case = 344, N monozygotes = 1,006).
Potential risk factors including aging, gender, smoking, severe sunburn, skin color, BMI and hor-
monal status were examined for association with sagging status in the Dutch individuals using mul-
tivariate logistic regression. We estimated the heritability of sagging eyelids in UK twins. Further-
more we conducted a genome-wide association study (GWAS) searching for single nucleotide
polymorphisms (SNPs) associated with sagging status in both the Dutch and UK individuals. We
identified age (OR=1.02 per year; 95%CI=1.01–1.03), male gender (OR=1.48; 95%CI=1.28–1.70),
current smoking (OR=1.28; 95%CI=1.08–1.51) and light skin color (OR=1.24, 95%CI=1.07–1.44)
as significant and independent risk factors for sagging eyelids. Heritability was estimated to be 57%.
Our GWAS revealed SNPs at ten loci associated with sagging status with suggestive evidence (5×10-
8 < P < 1x10-5), indicating EPHA8, SMYD3, KCNQ5, RIMS2, MYOF, BLNK, CDK17, and DLGAP1
as candidate genes potentially involved in the development of sagging eyelids. This is the first
observational study demonstrating that in addition to age and gender, skin color, smoking, and
genetic variants are important factors in the aetiology of skin sagging.
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Varying prevalence of depression in psoriasis according to assessment method: a systematic
review and meta-analysis
EA Dowlatshahi,1 M Wakkee,1 L Arends2,3 and T Nijsten1 1 Dermatology, Erasmus Medical
Centre, Rotterdam, Netherlands, 2 Biostatistics, Erasmus Medical Centre, Rotterdam,
Netherlands and 3 Insitute of Psychology, Erasmus University, Rotterdam, Netherlands
Psoriasis patients suffer from impaired Health Related Quality of Life but also show signs of depres-
sive symptoms. This study aims to compare depression in psoriasis patients to healthy controls, to
determine the prevalence of depression in psoriasis and to investigate how the method of assess-
ment of depression can affect this prevalence. We conducted a systematic literature search on pso-
riasis and depression in several databases. We compared mean values for depression questionnaires
between psoriasis patients and controls to obtain pooled Standardized mean differences (SMD)
and 95%CI, and depression rates according to questionnaires, antidepressant use, International Clas-
sification of Diseases (ICD) and the Diagnostic and Statistical Manual of Mental Disorders IV (DSMIV)
obtaining pooled OR. Further, we pooled mean values and proportions of depressed psoriasis patients
according to the different assessment methods. We included 100 studies, mostly conducted in ter-
tiary centres with only few population based studies. According to studies using questionnaires to
assess depression, psoriasis patients were significantly more depressed than healthy controls with
a SMD of 1.16 (95%CI 0.67-1.66). Five population based studies showed that psoriasis patients
had 1.6 higher odds of a depression according to the ICD than healthy controls (95%CI 1.40-1.76)
and also used more antidepressants (OR 4.24, 95%CI 1.53-11.76). The majority of the studies
included psoriasis patients without a healthy control group (n=73) and reported varying pooled rates
of depression in psoriasis depending on the assessment method: 28% for questionnaires, 12%
using the ICD, 19% using the DSMIV and 9% for antidepressant use. Psoriasis patients show more
signs of depression than their healthy pears. Interestingly, the prevalence of depression in psoriasis
varies between 9-28% and is highest when questionnaires are used to assess depression and low-
est when antidepressant use is measured.
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A pilot study using unannounced patients and moulage to measure melanoma detection
rates by internal medicine residents
C Hernandez1 and JK Robinson2 1 Dermatology, University of Illinois at Chicago, Chicago, IL
and 2 Dermatology, Northwestern Feinberg School of Medicine, Chicago, IL
Melanoma outcome disparities in skin of color have been attributed in part to low levels of primary
care physician training in its presentations. Unannounced standardized patients (SPs) are actors
placed in physicians’ practices to evaluate their behavior in a real clinical setting. This pilot study
tested the feasibility of using unannounced SPs and moulage (a mock clinical finding applied to the
SP) to determine internal medicine (IM) resident physicians’ melanoma detection rates for White
and Black SPs. Eight unannounced SPs, 4 White and 4 Black were evaluated by 8 third-year Uni-
versity of Illinois at Chicago IM residents. Two White and 2 Black SPs had a melanoma moulage
applied to the hypothenar eminence on the palm (hand) while 2 White and 2 Black SPs had the
moulage placed on arch of the sole (foot). Each group of SPs presented with a clinical scenario that
should prompt either a hand or foot examination. SPs were instructed not to point out the melanoma.
SPs audio-recorded their visits and documented whether the moulage was detected or not. Of the
8 unannounced SPs evaluated only 1, a White SP, had the moulage detected on the foot. SP record-
ings were content-analyzed using the Inventory of Diagnostic Thinking Processes (DTP) from the
Gale and Marsden model for clinical decision-making. This model describes specific decision-
making processes that occur as a physician attempts to solve a clinical problem and assists in deter-
mining the source of diagnostic errors. The most common DTP was “failure to make a specific
enquiry” since (7/8) residents failed to ask about the moulage. Melanoma detection rates for both
Whites and Blacks were low in the pilot study and it begins to highlight the need for greater empha-
sis on the clinical skin examination in medical education. Early detection remains one of the most
important interventions for melanoma. The failure of residents to notice the atypical lesion repre-
sents a lost opportunity to provide an intervention for their patients.
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Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neural-
gia in an older US population
SM Langan,1 L Smeeth,1 DJ Margolis2 and SL Thomas1 1 Dept of Epidemiology and Population
Health, London School of Hygiene and Tropical Medicine, London, United Kingdom and 2
Dept of Dermatology, University of Pennsylvania, Philadelphia, PA
Herpes zoster is common with serious consequences, notably post-herpetic neuralgia. Vaccine effi-
cacy against incident zoster and post-herpetic neuralgia has been demonstrated in clinical trials,
but effectiveness has not been studied in unselected general populations. It is critical to establish
vaccine effectiveness in a population unrestricted by region, full insurance or immune status. Our
objective was to assess zoster vaccine effectiveness in a general population-based setting. A cohort
study of 766,330 fully eligible individuals aged ≥65 years was undertaken in a 5% random sample
of Medicare who received and did not receive zoster vaccination between 2007 and 2009. Inci-
dence rates and hazard ratios for zoster and post-herpetic neuralgia were determined in vaccinated
and unvaccinated individuals. Analyses were adjusted for age, gender, race, low income, immuno-
suppression and important comorbidities associated with zoster, and then stratified by immuno-
suppression status. Vaccine uptake was low (3.9%) particularly among black people (0.3%) and
those with evidence of low income (0.6%). 13,112 US Medicare beneficiaries developed incident
zoster; the overall zoster incidence rate was 10.0 (95% CI 9.8-10.2) per 1,000 person-years in the
unvaccinated group and 5.4 (95% CI 4.6-6.4) per 1,000 person-years in vaccinees, giving an adjusted
vaccine effectiveness against incident zoster of 0.48 (95% CI 0.39-0.56). In immunosuppressed indi-
viduals, vaccine effectiveness against zoster was 0.37 (95% CI 0.06-0.58). Vaccine effectiveness
against post-herpetic neuralgia was 0.59 (95% CI 0.21-0.79). Vaccine uptake was low with varia-
tion in specific patient groups. In a general population cohort of older individuals, zoster vaccina-
tion was effective against incident zoster, including among those with immunosuppression. Impor-
tantly, our study is the first to fully examine and demonstrate vaccine effectiveness against post-herpetic
neuralgia.
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Epidemiology of anorectal melanoma in the United States: 1992-2009
A Callahan,1 WF Anderson,2 S Patel,1,3 JS Barnholtz-Sloan,1,4 JS Bordeaux,1,3,4 MA Tucker2 and
MR Gerstenblith1,3,4 1 Case Western Reserve University School of Medicine, Cleveland, OH, 2
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville,
MD, 3 Department of Dermatology, University Hospitals Case Medical Center, Cleveland, OH
and 4 Case Comprehensive Cancer Center, Cleveland, OH
Anorectal melanoma is a rare type of malignant melanoma that is not well-characterized. We, there-
fore, used the National Cancer Institute’s Surveillance, Epidemiology, and End Results 13 Registries
Database (SEER) to analyze anorectal melanoma in men and women from 1992 through 2009. There
were 228 anorectal melanoma cases with nearly 689,657,439 person-years of follow-up. Most of
the cases occurred in the rectum (38.6%). Incidence rates were highest among white women ages
75-84 years; 0.30 per 100,000 (95% CI: 0.22-0.40). During our study period, the estimated annual
percentage change in incidence rates rose statistically significantly among men (6.04%/year, CI
2.02-10.21) and women (4.25%/year; CI 1.58-6.99). More cases were found in southern latitudes
[< 38°, including San Francisco-Oakland, Hawaii, New Mexico, Atlanta, Los Angeles, San Jose-
Monterey, and Rural Georgia) than in northern latitudes (> 40°, including Connecticut, Detroit,
Iowa, Seattle (Puget Sound), Utah, and Alaska Native Tumor Registry), which contrasts with a prior
U.S. study that demonstrated an increased incidence in northern latitudes. Overall survival and
melanoma-specific survival was poor for men and women. The increasing incidence of anorectal
melanoma and poor survival rates in both men and women warrant further investigation and con-
firmation in other populations. Furthermore, the observed greater incidence in women and in south-
ern latitudes should be explored further in analytic studies.
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Thymic stromal lymphopoietin (TSLP) and atopic dermatitis (AD) in a longitudinal cohort
DJ Margolis, B Kim, AJ Apter, J Gupta and N Mitra University of Pennsylvania School of
Medicine, Philadelphia, PA
TSLP is a master initiator of allergic inflammation. In 2010, a study showed a decreased risk of AD
among children with TSLP rs1898671 variant. The goal of our study was to determine if TSLP genetic
variation was associated with AD persistence and whether it modified the effect of FLG loss of
function mutations in a white cohort. We assessed associations assuming an additive genetic model
and a mixed effects logistic regression. Genotyping for 14 tag SNPs in TSLP and for the four most
common European FLG mutations was performed using a custom Ilumina Goldengate SNP chip
(Illumina, San Diego, CA) and TaqMan® assays, respectively. Clinically, 429 white children from
the Pediatric Eczema Elective Registry (PEER) were evaluated every 6-months for an average of 5.7
(±1.4) years. Only rs1898671, with a minor allele frequency of 0.225 was associated with an increased
likelihood of a child reporting no symptoms of AD (Odds ratio (OR): 1.72, 95% CI: (1.11, 2.65))
during follow up. This association was minimally changed when the model was adjusted for gen-
der, presence of FLG mutation, and age of onset of AD (1.68 (1.09, 2.59)). Previously, FLG muta-
tions were associated with an increased persistence of AD among this white subcohort of PEER.
However, in this study, among those with FLG mutations, rs1898671 appeared to reverse this
effect. Those with FLG mutations and the rs1898671 variant had less persistent AD as compared to
those with FLG mutations only (5.68(2.18, 14.82)). While FLG mutations result in a more porous
skin barrier, TSLP likely promotes the immune response to antigens that breach the defective bar-
rier. These findings provoke the hypothesis that rs1898671 or a variant in linkage disequilibrium
may diminish TSLP activity thereby decreasing cutaneous inflammation and allergy. Further inves-
tigations, including fine-mapping and functional investigations, need to be conducted in order to
determine the causal variant.
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Prognostic factors in transformed mycosis fungoides: A retrospective analysis of 187 cases
R Talpur,1 D Sui2 and M Duvic1 1 Dermatology, UT MD Anderson Cancer Center, Houston, TX
and 2 Biostatistics, UT MD Anderson Cancer Center, Houston, TX
Large cell transformation (LCT) (>25% tumor cells with nuclei > 4 times normal size) of mycosis
fungoides (MF) is generally associated with aggressive clinical course and poor survival. In order to
identify prognostic clinical, histologic and immunophenotype predictors of outcome associated
with LCT, we performed a retrospective analysis of our cutaneous lymphoma database containing
1900 MF/Sézary syndrome (MF/SS) evaluated over 26 years. We identified 187 patients with biopsy
proven LCT in skin or nodes for overall incidence of 9.8%: 168 had LCT in skin only, 19 had LCT
in both skin and lymph nodes. Mean age was 59.57 years and male to female ratio was 1.2:1. As
expected, LCT was uncommon among early patch/plaque MF (Stage IA-IIA) 17.1% patients and
83%)of advanced Stage IIB-IVB patients. Progression to LCT within < 12 months after diagnosis
occurred in 155 patients (82.89%) whose OS was 4.7 yrs and compared to 32 patients (17.11%)
diagnosed with LCT within > 12 months after diagnosis whose OS was 7.13 (p=.08; NS). Death from
disease occurred in 68 of 162 (42%) with cause of death available. There was no difference in sur-
vival in patients with LCT in skin or skin and nodes. Median overall survival of LCT patients (4.79
yrs) was similar to non-LCT (T3) MF patients (6.24 yrs) and significantly worse than all MF patients
(26.26 years) (p=.001). OS for LCT patients > 60 years was 3.71 compared to 6.18 years in patients
<60 yrs (p=.0001). Median OS of patients with LCT and advanced stage was 3.72 yrs vs 5.96 years
for early stage MF (p=.0147). Sixty-seven of 187(35%) LCT patients had >10% expression of CD30
on tumor cells. In conclusion, by univariate analysis, risk factors associated with disease progres-
sion or death included advanced age, LCT diagnosis < 12 months of diagnosis, and presence of
CD30 expression > 10%.
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Pigmentary phenotype and race are incomplete predictors of Fitzpatrick skin type
SY He,1 WJ Boscardin,2 CE McCulloch,2 M Chren,1 E Linos1 and ST Arron1 1 Dermatology,
University of California, San Francisco, CA and 2 Epidemiology & Biostatistics, University of
California, San Francisco, San Francisco, CA
The Fitzpatrick skin phototype (FSPT) is a method to assess sunburn/tanning by evaluating patient-
reported sensitivity to UV. Physicians often estimate FSPT based on race or appearance rather than
asking the patient about burning or tanning. Physicians often assign ethnic minorities to FSPT IV-VI
based on skin color; this method has proved unreliable. Given the increasing ethnic diversity in the
US, we sought to clarify the assumption that FSPT can be visually estimated by determining whether
race and pigmentary phenotype are predictive of FSPT in a racially diverse population. 3386 peo-
ple completed a cross-sectional survey. Multivariate ordinal logistic regression was performed for
FSPT on predictors of sex, age, hair, eye, and constitutive skin color, and race. Ten-fold cross-vali-
dation was performed and the mean absolute error and weighted kappa were calculated to evalu-
ate accuracy. The entire range of FSPT I-VI was observed for all racial/ethnic groups. Hair, eye, and
skin color were all independent predictors of FSPT; race was also an independent predictor even
when controlling for pigmentary phenotype (p<0.01). The predictive model had a weighted kappa
statistic of 0.53 and mean absolute error of 0.916 for prediction within one level, suggesting that
constitutive pigmentation and race are incomplete predictors of FSPT. While FSPT can be estimated
by observation of pigmentation and race, these are incomplete predictors of tanning and burning
ability. Race was also an independent predictor of FSPT, suggesting that genetic factors beyond pig-
mentation underlie response to UV radiation. All FSPT were observed in all racial groups. Given
that the tendency to sunburn has been associated with skin cancer risk, accurate measurement of
FSPT in ethnic minorities may predict skin cancer risk in these populations.
585
SSc-overlap syndromes differ in disease progression from limited and diffuse SSc (on behalf
of all DNSS centers)
P Moinzadeh, T Krieg and N Hunzelmann University of Cologne, Cologne, Germany
Systemic sclerosis ( SSc) is a heterogeneous multisystem connective tissue disease, which origi-
nates as a consequence of an interaction between an altered immunologic process, vascular endothe-
lial cell injury as well as an excessive production and accumulation of collagen and other ECMs,
causing skin sclerosis and fibrosis of affected visceral organs. A very interesting subset includes
patients with overlap syndromes, presenting with SSc features as well as symptoms of other rheu-
matic diseases. These represent a very remarkable selection of scleroderma patients, categorized
either by the detection of specific antibodies, by specific clinical features and /or a certain genetic
background. Among all registered 3365 patients, 10% were classified as an overlap syndrome, while
48% were diagnosed with limited SSc and 30% with diffuse SSc. Within the overlap cohort 15 %
had anti-centromere antibodies (ACA) and 13% were anti-Scl-70 antibody positive, while the remain-
ing patients harboured other antibody specificities (66%). Within this group of 216 patients with
other antibodies, 32% were U1RNP positive, 16% showed PmScl antibodies (Ab), 24% Ro-, 11%
La-, 5% anti-Mi2-, 4% Jo1-, 2% PL-7-Abs, and 13 % were positive for rheumatoid factor. Detailed
analysis of different organ manifestations revealed, that 59% of overlap patients suffered from mus-
culoskeletal involvement, followed by 52% with GI-manifestation, 35% with lung fibrosis, 12%
with heart involvement, 11% with PAH and 7% with renal manifestation. The Kaplan-meier analy-
sis revealed a clear inclined position of overlap patients between patients suffering from the limited
and diffuse form of SSc, especially regarding lung fibrosis and heart involvement (log rank<0.0001).
The clinical data indicate that patients suffering from overlap syndromes have to be viewed as a sep-
arate SSc subset with a different course of disease, different proportional distribution of organ man-
ifestations and antibodies.
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Vitamin D intake and risk of incident psoriasis
JF Merola,1 J Han,1,2 T Li2 and A Qureshi1,2 1 Clinical Research Program, Department of
Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA and 2
Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s
Hospital, Harvard Medical School, Boston, MA
The purpose was to examine the association between dietary as well as supplementary vitamin D
intake and incident psoriasis in women. We conducted a cohort study of 70,436 US female nurses
aged 48-74 enrolled in the Nurses’ Health Study who did not have psoriasis at baseline in 1994
and who completed semi quantitative food frequency questionnaires in 1994, 1998, and 2002. The
incidence of clinician-diagnosed psoriasis was ascertained and validated by self-reported ques-
tionnaires. 520 confirmed incident psoriasis cases were documented during 945,643 person-years
of follow-up from 1994 June to 2008 June. Association between vitamin D intake and incident pso-
riasis was assessed using multivariable-adjusted cox regression analysis. After adjusting for age,
smoking, body mass index, calorie intake and alcohol use, there was no significant association
between total vitamin D intake (measured as dietary and supplementary vitamin D, combined) and
the risk of psoriasis. Compared with women whose dietary vitamin D intake <100 IU/d, multivari-
ate relative risks for psoriasis were 1.03 (95% CI, 0.77,1.39) for 100-199 IU/d, 1.06 (95% CI, 0.78,
1.44) for 200-299 IU/d, 0.91 (95% CI,0.62, 1.33) for 300-399 IU/d, and 1.07(95% CI,0.66,1.74)
for ≥400 IU/d (P,trend= 0.84). The multivariate relative risk for women who took supplementary vita-
min D ≥400 IU/d was 1.05 (95% CI,0.76,1.43) compared with women who did not take supple-
mentary vitamin D. In conclusion, our study does not support preventive roles of dietary or sup-
plemental vitamin D intake for incident psoriasis.
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Inverse relationship between melanoma death and sentinel lymph node metastases by age in
the SEER Databases (2003-2009)
MW Cavanaugh-Hussey,1 EW Mu,1 T Wang,1 CM Balch2 and S Kang1 1 Dermatology, Johns
Hopkins Medical Institutions, Baltimore, MD and 2 Surgical Oncology, University of Texas
Southwestern Medical Center, Baltimore, MD
It is known that elderly melanoma patients have lower survival rates than younger patients with
melanoma. Paradoxically, a few smaller institutional studies have found a lower frequency of sen-
tinel lymph node positivity in the elderly. This is the first study to examine these relationships across
all age groups in a large national sample. The US Surveillance Epidemiology and End Results (SEER)
Databases were queried to examine 122,721 melanoma cases from 2003 to 2009. Controlling for
tumor depth, prevalence rates of sentinel node involvement and melanoma death were assessed
for all age groups. The associations between age, nodal status, and mortality were then estimated
using logistic regression analyses, controlling for tumor depth, ulceration, primary tumor site, his-
tological subtype, and lymph node surgery. At each tumor depth >1 mm, older patients had less
frequent sentinel node involvement but higher melanoma mortality than younger patients (P<.001).
This inverse relationship was linear across all age groups. In multivariate regression analyses, >80
year-olds were less likely to be node positive compared to 0-20 year-olds (OR 0.38, 95% CI 0.26-
0.54). Yet, >80 year-olds were more likely to die of melanoma compared to 0-20 year olds (OR 6.60,
95% CI 3.44-12.69). Similarly, this inverse relationship was seen across all age groups in the mul-
tivariate analyses. In a large national sample, we found an inverse relationship between melanoma
death and sentinel lymph node positivity by age. This paradox highlights the need for further study
into age related differences in melanoma biology, immunological surveillance, and host response.
It also questions whether melanoma staging should take into account the age of a patient.
588
The Journal of Investigative Dermatology’s experience in its first six months on Facebook
R Gamble,1 B Gilchrest2 and R Dellavalle1,3 1 Dermatology, University of Colorado, Aurora,
CO, 2 Dermatology, Boston University, Boston, MA and 3 Dermatology, Veterans Affairs
Medical Center, Denver, CO
With the Journal of Investigative Dermatology (JID) having recently begun a Facebook page in July
2012, we reviewed post analytics and audience demographics to determine factors encouraging
audience participation. The top 5 posts [date posted; users reached] with the largest reach were:
Vitamin D, UVR and immunosupression [12/3/12; 802], Autoantibody differences in DLE and SLE
[12/4/12; 764], UV-induced wrinkle formation by induction of HSP70 expression in mice [11/30/12;
739], Immunity to sand fly saliva in rodents induces protection against leishmaniasis [12/3/12; 722],
Gene profiling of narrowband UVB-Induced skin injury [11/20/12; 720]. The top 5 posts [date posted;
users engaged] with most engaged users were: Sciton BroadBand Light treatments can change the
expression of genes associated with the aging process [11/14/12; 498], Punctate palmoplantar ker-
atoderma is caused by mutations in the AAGAB gene [10/23/12; 225], The role of systematic reviews
and meta-analysis in Dermatology [11/24/12; 209], The pathobiological mechanisms of psoriasis
[9/19/12; 140], Atopic dermatitis treatment [11/26/12; 133]. The top 5 posts [date posted; users talk-
ing] with most readers talking about them were: Sciton BroadBand Light treatments can change the
expression of genes associated with the aging process [11/14/12; 180], Atopic dermatitis treatment
[11/26/12; 77], Punctate palmoplantar keratoderma is caused by mutations in the AAGAB gene
[10/23/12; 65], The pathobiological mechanisms of psoriasis [9/19/12; 55], The role of systematic
reviews and meta-analysis in Dermatology [11/24/12; 48]. A diverse group accessed the Facebook
page including users from 83 countries. The top three countries were India (25%), Brazil (22%),
and the United States (10%). There was diversity among the popular posts, but the most popular
posts tended to either have a more immediate clinical impact than the average post, or to relate to
a prominent current topic in dermatology research (such as psoriasis and systematic reviews).
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Sun exposure, tanning bed usage and prevalence of atopic dermatitis
L Lin,1,2,4 J Han,1,2,3 Z Zhang,4 CA Camargo2,3 and AA Qureshi1,2 1 Clinical Research Program,
Department of Dermatology, Brigham and  Women’s Hospital, Harvard Medical School,
Boston, MA, 2 Channing Division of Network Medicine, Department of Medicine, Brigham
and Women’s Hospital, Harvard Medical School, Boston, MA, 3 3Department of
Epidemiology, Harvard School of Public Health, Boston, MA and 4 4School of Public Health,
Guangxi Medical University, Nanning, China
We sought to investigate the associations between eczema (atopic dermatitis, short as AD) and out-
door sun exposure, tanning bed usage, and UV index of residence. We included a total of 66,750
participants from the large well-characterized Nurses’ Health Study II cohort (NHSII) established in
1989. Lifetime prevalence of eczema was attained from the 2009 NHSII questionnaire. We used
multivariate logistic regression models to estimate odds ratios (OR) to AD for sun exposure at high
school/college and at age 25-35; tanning bed usage at high school/college and at age 25-35; and
UV index at birth place, age 15, and age 30. We included 66,750 participants who completed the
NHSII 2009 questionnaire and had answered questions on eczema, sun exposure and tanning bed
usage. 6,764 AD cases were reported. We observe prevalence of AD decreased as outdoor sun expo-
sure increased. Compared with the group with <1hr/wk of direct sun exposure in high school/col-
lege, the multivariable-adjusted OR of AD was 0.88(95% CI:0.80-0.98) for 2-4hr/wk, and 0.87(95%
CI:0.79-0.96) for 5+hr/wk (p trend, 0.03). The multivariable-adjusted OR of AD for direct sun expo-
sure at age 25-35 was 0.85(95% CI:0.78-0.93) for 2-4hr/wk, and 0.82(95% CI:0.75-0.89) for 5+hr/wk
(p trend, <0.001). However, we did not find a significant association between tanning bed usage
with AD prevalence in either high school/college or age 25-35. No significant association was found
between UV index of residence and AD prevalence. In conclusion, direct outdoor sun exposure
may be associated with lower AD prevalence.
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Comparison between treatments for adult and adolescent acne: Response to treatments and
challenges to study
M Diakow,1 S Rivas,1 T Mammone,2 W Lee1 and AR Shalita1 1 Dermatology, SUNY-Downstate
Med Ctr, Brooklyn, NY and 2 Basic Science Research, Estee Lauder Companies, Melville, NY
Acne vulgaris is a chronic inflammatory disease known to be a common condition in adolescents.
However, an increasing number of patients over the age of 25 are being identified and referred for
acne treatment. There has been limited data in the literature on acne in this adult cohort. We con-
ducted a retrospective review of 5 clinical acne studies with a total of 94 patients. We found the
prevalence of adult acne to be 26-45%. Acne in this cohort of adult patients differs from the acne
seen in younger patients. Adult acne tends to be more common in women. Female adult acne patients
comprised 68% of patients. In terms of lesion type, our adult acne patients had similar numbers of
inflammatory and non-inflammatory lesions, 47% vs. 53%, respectively, whereas the adolescent
acne patients had the values of 40% vs. 60%. Adult acne lesions are seen distributed predomi-
nately on the chin and jaw-line. Furthermore, the psychosocial impact of acne for adolescents is
well documented. In adult patients the negative effects on quality of life need to be addressed through
effective treatment options. Therefore, assessing the distinguishing features of acne in this adult
cohort and assessing responsiveness to treatments remains a critical step towards developing treat-
ments for adult patients. Across the five treatment modalities response to treatment was assessed
objectively by calculating the percent change in inflammatory and non-inflammatory lesion counts
from baseline. Across the five studies, adult acne patients showed substantial improvement. Topi-
cal retinoid use among adult acne patients showed significant reduction (p<0.05) in lesion counts
– 59% and 73%, respectively in inflammatory and non-inflammatory lesions. Blue-light therapy was
also found to be effective for adult acne treatment, 43% and 50%, respectively in inflammatory and
non-inflammatory lesions. Several factors including problems with sensitive and dry skin in this
group might pose potential problems for study and treatment options.
592
What are the most important questions to be answered in dystrophic epidermolysis bul-
losa(DEB) research? Results from the Spanish prioritization partnership
P Dávila-Seijo,1 ÁNGELA Hernández-Martín,2 E Morcillo-Makow,3 R De Lucas,4 E Domínguez,3
N Romero,3 E Monrrós,3 M Feito,4 L Carretero,3 B Aranegui6,5 and I García-Doval6,1 1
Dermatology, Complexo Hospitalario de Pontevedra, Pontevedra, Spain, 2 Dermatology,
Hospital Niño Jesús, Madrid, Spain, 3 The Dystrophic Epidermolysis Bullosa Research
Association (DEBRA) Spain, Marbella, Spain, 4 Dermatology, Hospital Universitario de la Paz,
Madrid, Spain, 5 Dermatology, Clínica Universitaria de Navarra, Madrid, Spain and 6
Research Unit, Fundacion AEDV, Academia Española de Dermatologia y Venreología (AEDV),,
Madrid, Spain
DEB is a rare genetic disorder that causes blisters with minor trauma in skin and mucosa. Patients
and health care professionals(HCPs) have to deal with numerous complications for which there is
frequently non evidence-based therapies. Because the research budget is limited and the number
of uncertainties is large, prioritizing the most important is mandatory. Priority Setting Partnership(PSP)
methodology tries to ensure that those who fund health research are aware of what matters to both
patients and clinicians. Objectives: To find and prioritize the most important uncertainties about
treatment shared by DEB patients, carers and HCPs. Methods: A DEB PSP was done following the
guidelines of the James Lind Alliance. Uncertainties were obtained from patients, carers and expert
clinicians and they were prioritized in an explicit process. Results: In the consultation stage, 323
uncertainties were submitted by 58 participants. The duplicated and non-treatment uncertainties
were removed and the remainder were reduced to a list of 24 most popular questions through an
online voting process. They were prioritized in a final workshop where a final top 10 therapy uncer-
tainties was selected.It includes interventions in wound care, itch and pain management, treatment
and prevention of syndactyly, cancer and future therapies. Conclusions: The top 10 treatment uncer-
tainties on the management of DEB provides guidance for researchers and funding bodies, in an
effort to promote research in questions that are important to both clinicians and patients.
594
Patient-assessed disease severity is a strong determinant of health-related quality of life in
chronic hand eczema
C Apfelbacher,1 E Weisshaar,2 S Molin,3 A Bauer,4,7 V Mahler,5 U Matterne,2 M Weiss,2 J Schmitt,6,7
T Ruzicka,3 P Elsner8 and T Diepgen2 1 Institute of Epidemiology and Preventive Medicine,
University of Regensburg, Regensburg, Germany, 2 Department of Clinical Social Medicine,
University of Heidelberg, Heidelberg, Germany, 3 Department of Dermatology and
Allergology, Ludwig-Maximilians-University Munich, Munich, Germany, 4 Department of
Dermatology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden,
Germany, 5 Department of Dermatology, University of Erlangen, Erlangen, Germany, 6
Institute and Outpatient Clinics of Occupational and Social Medicine, Technical University
Dresden, Dresden, Germany, 7 UniversityAllergyCenter, University Hospital Carl Gustav
Carus, Technical University Dresden, Dresden, Germany and 8 Department of Dermatology
and dermatological Allergology, Friedrich-Schiller-University Jena, Jena, Germany
The purpose of this study was to analyse determinants of health-related quality of life (HrQoL) in
patients with chronic hand eczema (CHE), using data from the German carpe (German acronym:
Chronisches Handekzem-Register zum Patienten-Langzeitmanagement) registry. HrQoL was meas-
ured by the Dermatology Life Quality Index (DLQI). Demographics, disease-related variables,
treatment-related variables, predisposition, health care utilization and treatment experience were
entered into a multivariable linear regression model. Median DLQI was 8.00 (N=992). Self-assessed
disease severity emerged as the strongest significant determinant (β=0.38) in the final model (N=582),
followed by having experienced unpleasant side effects (β=0.16), general treatment burden (β=0.11),
physician global assessment (β=0.11), atopic skin diathesis (0.09) and having visited a GP (0.09).
Age, gender, body mass index, itch, localisation and duration of CHE, satisfaction with care as well
as type of treatment did not emerge as significant determinants in the final model. 39% of the vari-
ance were explained by the variables considered. To conclude, self-assessed disease severity is a
powerful determinant of HrQoL in CHE. Unpleasant side effects require special attention in the care
of patients with CHE.
593
High prevalence rates of contact allergy in the European general population 
TL Diepgen,1 L Naldi,2 M Bruze,3 S Cazzaniga,2 P Coenraads,4 P Elsner,5 R Ofenloch1 and
A Svensson6 1 Clinical Social Medicine, University Hospital Heidelberg, Heidelberg, Germany,
2 Centro Studi GISED, Bergamo, Italy, 3 University Hospital Malmö, Malmö, Sweden, 4
Department of Dermatology, University Hospital Groningen, Groningen, Netherlands, 5
Department of Dermatology and Allergology, University Hospital Jena, Jena, Germany and 6
University Hospital Coimbra, Coimbra, Portugal
The objective was to obtain reliable estimates of the prevalence rates of skin diseases and contact
allergy to common allergens in the general population. The methods include cross-sectional study
of a random sample from the general population, aged 18 to 74 years, in 6 different European areas
(Sweden, The Netherlands, East-Germany, West-Germany, Italy, Portugal). In total 12,377 subjects
were interviewed and a random sample (n=3,119) patch tested to True test panel 1, 2 and 3. A pos-
itive patch test reaction (at least a “+” reaction) is considered as a proxy for contact allergy. The
reported lifetime prevalence rates (age-standardized) of diagnoses confirmed by a physician were
as follows: contact dermatitis n=1025 (8.4%; 95%CI 8.0-8.8), atopic dermatitis n=870 (7.0%; 95%
CI 6.7-7.3), other types of eczema n=1642 (13.4%; 95% CI 12.9-13.6). In total, 18.9% of all patch
test subjects had at least one positive reaction to an allergen of True test panel 1 (men 9.0%, women
27.0%), 8.8% against at least one allergen of panel 2, and 1.0% at least one allergen of panel 3. At
least one reaction against an allergen of True test panel 1, 2, or 3 was seen in 25.3% (men 15.7%,
women 33.2%). The highest age-standardized prevalence rates (<1%) were found for Nickel sulfate
(14.6%; 95% CI 13.7-15.5), Thiomersal (5.1%; 95% CI 4.5-5.7), Cobalt chloride (2.2%; 95% CI 1.8-
2.6), and p-tert-Butylfenolformaldehyderesin (1.3%; 95% CI 1.0-1.6). In conclusion, contact allergy
is frequent in the general population and needs a carefully interpretation of its clinical relevance.
591
High prevalence rates of occupational hand eczema among dental workers in Japan
K Minamoto,1 T Watanabe2 and T Diepgen3 1 Department of Preventive and Environmental
Medicine, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan, 2
Watanabe Dental Clinic, Kumamoto, Japan and 3 Department of Social Medicine,
Occupational and environmental dermatology, University of Heidelberg, Heidelberg,
Germany
Objectives: To estimate the prevalence rates of work related hand eczema and its risk factors in
dental workers in Japan. Methods: Population based cross sectional study among workers in den-
tal clinics in Kumamoto city, Japan. Self-reported questionnaire based on the validated Nordic Occu-
pational Skin Questionnaire 2002, consisted of hand eczema history, allergic disease history, glove
use, hand washing, and other risk factors. In addition, patch testing was preformed with 25 den-
tistry-related allergens in a subsample. Results: Out of 309 dental clinics to which the question-
naires were sent 97 clinics responded with 529 workers in total (dentists 19.5%, dental hygienists
50.3%, dental technicians 4.2 %, assistants 14.7%, and receptionists 11.3%). The mean age was
37.3 years and 78.1% of the 529 dental workers were female. In total, 55.1% of those workers
answered to have a life-time history of hand eczema. The one-year prevalence and point preva-
lence were 38.9% and 18.7%, respectively. The highest prevalence rates were found in dental hygien-
ists, assistants, and receptionists. The most frequent risk factors for work related hand eczema were
soap for hands, gloves, powder of gloves, disinfectants of hands, alcohol, detergents for tools. 51
workers were patch tested. 2 of those were diagnosed as allergic contact dermatitis to acrylates and
4 to rubber chemicals. Conclusions: The prevalence rates of work-related hand eczema in dental
workers are high and measures of primary and secondary prevention have to be established in Japan.
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Black henna tattoos but not hair colorants are an important risk factor for contact allergy to
p-phenylene diamine in the European general population 
TL Diepgen,1 L Naldi,2 M Bruze,3 S Cazzaniga,2 P Coenraads,4 P Elsner,5 M Goncalo,6
R Ofenloch1 and A Svensson3 1 Department for Clinical Social Medicine, University Hospital
Heidelberg, Heidelberg, Germany, 2 Centro Studi GISED, Bergamo, Italy, 3 University
Hospital Malmö, Malmö, Sweden, 4 Dept. of Dermatology, University Hospital Groningen,
Groningen, Netherlands, 5 University Hospital Jena, Jena, Germany and 6 University Hospital
Coimbra, Coimbra, Portugal
Objectives: To assess the prevalence rate of contact allergy to p-phenylene diamine (PPD) and its
risk factors in the general population in different European countries. Methods: In a cross-sectional
study a random sample of the general population, aged 18 to 74 years, was investigated in 6 Euro-
pean areas (Sweden, The Netherlands, East-Germany, West-Germany, Italy, Portugal), 10,425 sub-
jects were interviewed and a random sample (n=2,739) patch tested to PPD. Results: In total, 5286
(50.9%) reported to have used hair colorants at least once in their lifetime (females 78%, males
20%) and 35% used hair colorants during the last 12 months. Hair colorants avoidance because of
any skin problem during lifetime was reported by 624 subjects (6%). 570 subjects (5.5%) had used
black henna tattoos in lifetime. The overall age-standardized prevalence rate of PPD contact allergy
was 0.8% (95% CI 0.6-1.0%) in both men and women, and hair colorant lifetime users and non
users with no statistically significant differences. However the prevalence in black henna tattoo users
was 3.2% vs. 0.6% in non-users (p< 0.001). A clinically relevant positive patch test reaction to PPD
related to hair colorants (defined as lifetime avoidance of hair colorants and itchy skin rash on the
scalp/face/ears during lifetime) was found in 0.1% (95% CI 0.0-0.2%). A strongly significant asso-
ciation with PPD positivity was observed for subjects who had black henna tattoos in their lifetime,
with an age and gender adjusted OR of 9.33 (95% CI, 3.45-25.26, p<0.001). Conclusions: Black
henna tattoos are an important risk factor for PPD contact allergy in Europe.
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The impact of localisation on the association of itch and acne. Results from a population sur-
vey among adolescents
F Dalgard and J Halvorsen University of Oslo, Oslo, Norway
Two small studies have shown an association between adolescent acne and itch. However, there is
a need for population studies to better examine this relationship, especially regarding the localisa-
tion of lesions. The objective of this study was to examine the association between localisation of
acne and itch in a large sample of adolescents from the general population in Norway. The design
was a cross-sectional population-based study. All 18 or 19 year olds in their final year of schooling
living in Oslo were invited to participate in our questionnaire. In total, 4744 adolescents were invited
and 3775 (80%) completed the questionnaire. Study participants were asked to rate current sever-
ity of acne and itch intensity. The prevalence of itch among adolescents with facial acne was 17.6%
(72/409), and the prevalenc of itch among adolescents with acne on other body sights was 16.0%
(12/75). In an adjusted logistical regression analysis controlled for mental distress, sex, family income
and ethnicity, the adjusted odds ratio for acne and current itch was 2.43 (1.70-3.46) for those with
facial lesions compared to 2.21 (1.05-4.64) among those with lesions on other body parts. The con-
clusion is that there is a higher and significant association between acne and itch among adoles-
cents with facial lesions. This should be kept in mind in the management of adolescents with facial
acne.
597
International validation of a quality of life instrument specific to cosmetics and physical
appearance: The BeautyQoL
A Beresniak,1 GG Krueger,2 S Talarico,3 K Tsutani,4 G Duru,5 J Auray,5 S Aractingi6 and Y de
Linares7 1 Research, Data Mining Int., Geneva, Switzerland, 2 Dermatology, Univ. of Utah,
SLC, UT, 3 Dermatology, Univ. of Sao Paulo, Sao Paulo, Brazil, 4 Public Health, Univ.of Tokyo,
Tokyo, Japan, 5 Research, Cyklad, Lyon, France, 6 Dermatology, Paris-Descartes Univ., Paris,
France and 7 Research Innovation, L’Oreal, Paris, France
Objective: The BeautyQol instrument is a multi-dimensional self administered questionnaire which
has been specifically developed over three years in 16 languages for assessing the impacts of cos-
metic products and physical appearance on Quality of Life (QoL). This study reports the main fea-
tures of the validation process. Methods: An acceptability study was carried out on 874 subjects in
France, UK, Germany, Spain, Sweden, Italy, Russia, USA, Brazil, Japan, India (Hindi and English
languages) China and South Africa (Zulu, Sotho and English languages). 3231 subjects were then
further recruited for completing i) the BeautyQoL questionnaire ii) key clinical skin attributes iii)
the SF-36 generic QoL questionnaire and iv) a socio-demographic questionnaire. Psychometric
properties, construct validity, reproducibility, internal and external consistency were evaluated.
Results: Acceptability was high among the 16 cultures. The validation process condensed the ques-
tionnaire into 42 questions structured in five dimensions, explaining 76.7% of the total variance:
Social Life, Self confidence, Psychological life, Energy and Attractiveness. Internal consistency was
high (Cronbach alpha coefficients between 0.932 and 0.978). Reproducibility at 8 days was satis-
factory in all dimensions. An algorithmic scoring procedure allows calculating an overall score
(index) and five sub-scores for each dimensions (profile). External validity testing revealed that the
five BeautyQol scores correlated significantly with all SF-36 scores, Physical Function excepted.
Conclusions: Results demonstrate both the validity and reliability of the BeautyQol questionnaire
as the very first international instrument specifically dedicated to cosmetic products and physical
appearance.
598
Latent Ccass analysis of 697 patients with non-segmental viiligo identify of two clinical sub-
types
K Ezzedine,1 A le Thuaut,2 T Jouary,1 J Seneschal,1 A Taieb1 and S Bastuji-Garin2 1 Dermatology,
Hôpital St-André, Bordeaux, France and 2 Public Health and Statistics, (1) Univers i té
Paris Est Créteil, LIC EA 4393 ; AP-HP, Hôpital Henri-Mondor, Créteil, France
Non-segmental vitiligo (NSV) is a disease with variable clinical course. Our objective was to iden-
tify underlying subtypes of NSV that best explain the diversity NSV. We prospectively collected
data of 697 consecutive new cases of NSV between 2007 and 2012. Latent class (LC) analysis was
used to identify homogeneous groups of patients with similar clinical patterns. Demographic char-
acteristics, localisation of lesions, disease activity and triggering factors were compared across LC.
Median patient age was 33 years ; median age at onset was 19 years (range, 0.25-74). A two-class
model showed the best fit (minimization of Bayesian Information Criteria). The LC1 patients (63%
of the sample) had a high probability of late onset of the disease (0.93), and a lower probability of
associated halo nevi (0.16), Koebner phenomenon (0.40), family history of vitiligo (0.25) and cani-
tia (0.24). The LC2 patients (37%) had high probabilities of very early onset of the disease before
the age of 12 (0.92), associated halo nevi (0.40), Koebner phenomenon (0.47), lower surface involve-
ment (< 3% of the body surface, 0.66); and family history of vitiligo (0.40). Logistic regression com-
paring LC1 and LC2 patients showed that involvement of the head was linked to LC1 (85.5% vs
75.4% for LC2) (p<0.001) whereas trunk and limbs localizations were more often seen in LC2
(respectively 69.8%; 81.9%) than in LC1 (respectively 59.0%; 65.3%). In addition, combination wih
atopic dermatitis or with another autoimmune disease was linked to LC2 as it was the case for
familial background of autoimmune thyroiditis and other auoimmune disease. LC analysis allows
identifying 2 distinct subtypes of NSV. This classification is in agreement with the current knowl-
edge of vitiligo and may help to improve our understanding of autoimmunity/inflammation with
respect to predisposing genetic factors already identified.
599
Incidence and mortality of bullous pemphigoid in Olmsted County, Minnesota, USA over
five decades
C Weaver, C Lohse, M Pittelkow, M Camilleri, M Al-Hashimi, A Weaver and C Wieland
Dermatology, Mayo Clinic, Rochester, MN
Bullous pemphigoid (BP) is a chronic autoimmune blistering disease that occurs predominantly in
the geriatric population. Studies from Europe have shown an increased incidence of BP, and there
is evidence to suggest BP is associated with an increased mortality rate. The Rochester Epidemiol-
ogy Project was used to identify 101 patients who were residents of Olmsted County, Minnesota at
their first lifetime diagnosis of bullous pemphigoid (BP) between January 1, 1950 and December
31, 2009. Incidence rates per 100,000 person-years were calculated using incident cases of BP as
the numerator and age- and sex-specific estimates of the population of Olmsted County, Minnesota
as the denominator. The age- and sex-adjusted incidence of BP was 2.6 per 100,000 person-years
(95% confidence interval [CI] 2.1-3.1). Age-adjusted incidence was 2.5 per 100,000 person-years
(95% CI 1.9-3.1) for females compared to 2.7 per 100,000 person-years (95% CI 1.8-3.5) for males
(p=0.65). Incidence of BP increased significantly with age at diagnosis (p<0.001) and over time
(p<0.001). Overall survival was estimated using the Kaplan-Meier method. Estimated overall sur-
vival rates (95% CI; number still at risk) at 2, 4, 6, 8, and 10 years following diagnosis were 71%
(62 – 80; 64), 53% (43 – 64; 47), 39% (30 – 50; 31), 31% (23 – 43; 23), and 26% (18 – 38; 15),
respectively. In comparison, the survival rates at these time points expected in the Minnesota white
population were 85%, 72%, 61%, 51%, and 42%, respectively. The survival observed in the inci-
dent BP cohort was significantly poorer than expected (p<0.001). Patients with bullous pemphigoid
had a standardized mortality ratio of 1.82 (95% CI 1.42 – 2.28). These results from the United
States support previous reports of increased, though less marked mortality of BP compared to that
reported in Europe.
600
Reliability study of four objective outcome measures for atopic dermatitis
AQ Tran,1,3 JP Lazo-Dizon,1,3 J Kim,1,3 BS Daniel,1,3 SS Venugopal,1,3 LM Rhodes,1,3 MG Laws2 and
DF Murrell1,3 1 Department of Dermatology, St George Hospital, Sydney, NSW, Australia, 2
Kirby Institute, Sydney, NSW, Australia and 3 University of New South Wales, Sydney, NSW,
Australia
It is not known which objective disease extent measure for atopic dermatitis is the most reliable.
This study compared the inter-rater and intra-rater reliability of the four most commonly used out-
come measures for atopic dermatitis: the objective SCORing Atopic Dermatitis (SCORAD), Eczema
Area and Severity Index (EASI), Six Area, Six Sign Atopic Dermatitis (SASSAD) and Three Item
Severity index (TIS), as well as analysing their correlation to three QOL instruments: the Patient-
Orientated Eczema Measurement, Child/Dermatology Life Quality Index and SkinDex-29. After
power calculations to determine the minimum number required, 12 atopic dermatitis patients hav-
ing different degrees of severity were assessed on the same day by 5 independent trained derma-
tology assessors. Reliability was measured using the intra-class correlation coefficient calculated
through one-way random effect ANOVA and Bland-Altman plots. Correlation between subjective
and objective outcome measures was computed using the two-tailed Spearman’s rho correlation
with scatterplots. EASI demonstrated a high intra-rater and moderate inter-rater reliability, ICC=0.886
(95% CI: 0.744-0.952) and ICC=0.73 (95% CI=0.5 – 0.9), respectively. SASSAD showed moderate
intra-rater and inter-rater reliabilities, ICC=0.720 (95% CI = 0.424-0.878) and ICC=0.68 (95%
CI=0.44-0.88). TIS showed high intra-rater reliability ICC=0.886 (95% CI: 0.744-0.952) but low
inter-rater reliability ICC=0.497 (95% CI=0.233–0.785). Objective SCORAD showed low intra-rater
and inter-rater reliability, with ICC of 0.446 (95%CI=0.037-0.730) and 0.498 (95% CI= 0.234–0.785),
respectively. Only SASSAD demonstrated moderate correlation with SkinDex-29 ρ=0.611 (p=0.035).
In conclusion, this study found that the EASI score was the most reliable objective outcome meas-
ure and supports the use of EASI as a routine extent measure for atopic dermatitis studies and pos-
sibly for routine clinical use.
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Inpatient pseudocellulitis: Assessing the extent of the problem through dermatology consul-
tation services
L Strazzula,1 J Cotliar,2 LP Fox,4 S Gee,3 SL Hughey,5 K Shinkai4 and D Kroshinsky1 1
Massachusetts General Hospital, Boston, MA, 2 Northwestern Medical Center, Chicago, IL, 3
University of California Los Angeles Medical Center, Los Angeles, CA, 4 University of California
San Francisco Medical Center, San Francisco, CA and 5 University of Alabama, Tuscaloosa, AL
Due to the many dermatological conditions that can mimic cellulitis, pseudocellulitis is commonly
encountered by inpatient dermatology consultation teams. In order to better quantify and qualify
the nature of this problem, we conducted a retrospective review of inpatient dermatology consul-
tations in 2008 across four academic medical centers to assess the number of consultations requested
for cellulitis, the incidence of pseudocellulitis, and risk factors associated with the diagnosis. In
2008, a total of 1,430 inpatient dermatology consultations were conducted at Massachusetts Gen-
eral Hospital, University of California Los Angeles Medical Center, University of Alabama Medical
Center, and University of California San Francisco Medical Center. Of these, 75 (5.24%) were
requested for the evaluation of cellulitis. There were 34 women and 36 men with a mean age of
56.5 years. 65 (86.67%) of these patients were admitted to the hospital for the evaluation and treat-
ment of their rash. After evaluation by dermatology, 20 (26.67%) patients were found to truly have
cellulitis whereas 55 (73.33%) patients were diagnosed with pseudocellulitis. The most common
mimicking diagnoses were stasis dermatitis (28%), contact dermatitis (12%), and tinea pedis (10.67%).
The most common risk factors found in all patient evaluated for cellulitis were a history of skin dis-
ease (24%), diabetes mellitus (19%) and active cancer (17.33%). The misdiagnosis of cellulitis is a
significant problem among hospitalized patients. Early dermatology consultation in order to estab-
lish a correct diagnosis may decrease unnecessary antibiotic usage and shorten hospital stays. Obtain-
ing a dermatology consultation in the outpatient or emergency room setting may be a cost-effec-
tive strategy to decrease overall hospital admission rates.
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Life-style factors associated with hidradenitis suppurativa
VJ Reeder,1 DA Gold,1 M Mahan,2 IH Hamzavi1 and HW Lim1 1 Department of Dermatology,
Henry Ford Medical Center, Detroit, MI and 2 Department of Public Health Services, Henry
Ford Medical Center, Detroit, MI
Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the skin that is incompletely
understood. Knowledge of disease associations may further the comprehension and management
of this condition. Our aim was to create a formal database of information gathered from individu-
als with the diagnosis of HS seen in a specialty dermatology clinic. First, a standard, self-reported
questionnaire on life-style factors was administered to 88 patients. Subsequently, a retrospective
chart review from January 1, 2011 to May 31, 2012 was performed. Charts of patients with the ICD
9 code for HS were evaluated. 366 subjects who met clinical criteria for HS were included in the
database. A control population for the database was created from subjects seen in the same clinic
during the same time period for the diagnoses of keloids or verruca vulgaris using the matching cri-
teria of age +/- 5 years, race and gender. Based on the self-reported questionnaire results, 69.9% of
HS patients were obese, 49% of HS patients admitted to consuming fast-food two or more times
per week, and 56.3% of HS patients reported no leisure-time physical activity. Subsequent review
of the HS database revealed that in patients with the appropriate data available, 74.7% (204 of 273)
HS subjects were found to be obese while only 25.3% (69 of 320) of the controls met this criterion.
This was statistically significiant (p<0.001) and the odds ratio was 3.52 (2.48, 5.00). 43.8% (98 of
224) of HS patients and 22.5% (56 of 249) of controls were noted to have hypertriglyceridema. This
was statistically significant (p<0.001) and the odds ratio was 1.54 (1.07, 2.22). 54.4% (199) of sub-
jects were black and 25.7% (94) of subjects were white. The average age was 39.2 years. There is
a significant relationship between lifestyle factors and this disease, which should further be inves-
tigated to evaluate a possible metabolic pathway for HS.
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Clinical factors and outcomes associated with invasive melanoma biopsy transection
JL Woodcock,1 A Bowen,1 Y Zhang,2 G Stoddard2 and K Callis Duffin1 1 Dermatology, University
of Utah, Salt Lake City, UT and 2 School of Medicine, University of Utah, Salt Lake City, UT
A recent audit of dermatopathology reports from the University of Utah Department of Dermatol-
ogy revealed that 31% of invasive melanomas biopsies were deeply transected. To gain further
insight, chart review of 85 invasive melanoma cases biopsied by departmental providers from 6/1/10
to 5/10/11 was conducted. A mixed effect model was used to adjust for cluster effects within providers.
Some of the clinical factors included in this model were the dermatopathologist evaluating the spec-
imen, patient age, sex, and past medical history; family history of melanoma, whether the clinician
expressed concern regarding melanoma on the pathology requisition, biopsy site, and type of biopsy.
Histologic characteristics included in the model were Breslow depth, Clark level, type of melanoma,
and presence of lateral transection. Some of the outcome variables that were assessed included exci-
sion margins, whether residual melanoma was present on re-excision, whether sentinel node biopsy
was performed, and whether the sentinel node biopsy was positive. This study revealed that all
deep transections occurred with shave biopsies (p = 0.05). Other clinical factors that were statisti-
cally associated with transection included lack of clinical suspicion for melanoma (p = 0.02), female
patient (p = 0.03), and non-trunk location (p=0.05). Patients with deeply transected melanomas
were more likely to get sentinel node biopsies (71% vs. 30%, p = 0.001). Given that all transected
melanomas were biopsied via shave technique, questions arise as to why this technique was cho-
sen by clinicians. Decreased diagnostic accuracy is a possibility given that a lack of clinical suspi-
cion was significantly associated with biopsy transection. Concern regarding cosmesis or the time
constraints of an excisional biopsy may cause clinicians to compromise optimal clinical practice.
Further studies are needed to elucidate these factors, but the increased rate of sentinel node biop-
sies in transected melanomas makes this an important clinical question.
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Fragrance contact allergy in the European general population 
TL Diepgen,1 L Naldi,2 M Bruze,3 S Cazzaniga,2 P Coenraads,4 P Elsner,5 M Goncalo,6
R Ofenloch1 and A Svensson3 1 Department for Clinical Social Medicine, University Hospital
Heidelberg, Heidelberg, Germany, 2 Centro Studi GISED, Bergamo, Italy, 3 University
Hospital Malmö, Malmö, Sweden, 4 University Hospital Groningen, Groningen, Netherlands,
5 University Hospital Jena, Jena, Germany and 6 University Hospital Coimbra, Coimbra,
Portugal
Objectives: To determine the prevalence of fragrance contact allergy in the European general pop-
ulation and to assess the clinical relevance of positive patch test reactions to different fragrances.
Methods: Cross-sectional study in a random sample of the general population, aged 18 to 74 years,
in 6 European areas (Sweden, The Netherlands, East-Germany, West-Germany, Italy, Portugal), 12,377
subjects were interviewed about lifetime, 1-year and point prevalence of any skin disease and his-
tory of exposure to products containing fragrances, metals, plastics, rubber, leather, hair dye, with
frequency and pattern of use. A random sample (n=3,119) patch tested to the European standard
series True test panel 1, 2, 3 and 20 fragrances in Finn Chambers. Results: The conservative preva-
lence of fragrance contact allergy (defined by the existence of a positive patch test to Fragrance Mix
I (FM I) or Fragrance Mix II (FM II) or any of the individual materials in either FM I or FM II or Peru
Balsam or sesquiterpene lactones or 3 and 4-(4-Hydroxy-4-methylpentyl)-3-cyclohexene-1-car-
boxaldehyde (HMPCC) that show clinical relevance defined conservatively as lifetime avoidance
of scented products and contact dermatitis in a lifetime or an itchy skin rash lasting more than 3
days in a lifetime, respectively is 0.8% and 1.9%, respectively. This compares to a prevalence of up
to 14% reported in clinics in dermatitis patients. The prevalence rates of contact allergy to fragrances
in females are about two times higher than in males in very country. Conclusions: There was a sub-
stantially lower prevalence rate of fragrance contact allergy in the general population in Europe as
compared to previously published clinical data.
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Pilot study of skin aging peculiarities in patients with metabolic syndrome
J Janovska,1 J Voicehovska,2 J Kisis,1 R Kleina3 and R Karls1 1 Dermatology, Riga Stradinsh
University, Riga, Latvia, 2 Internal Disease, Riga Stradinsh University, Riga, Latvia and 3
Pathology, Riga Stradinsh University, Riga, Latvia
Introduction: Overweight and obesity in youth is a worldwide public health problem. Worldwide
approximately 15 % of population has got a metabolic syndromes (M. Hanefeld 2010) aged 40- 75
years old. Metabolic syndrome involves damage to various organs via oxidative stress or inflam-
mation, similar to the changes associated with aging. Aim: The aim of our pilot research is to com-
pare skin histological condition in patients with metabolic syndrome (MS) and without it. Material
and methods: Generally we have evaluated 13 patients, 7 of them had MS. The research was divided
into several steps: clinical examination, blood tests and punch biopsy. Punch biopsy 3-4 mm deep
was taken from the dorsal surface of the palm. Specimens were stained with haematoxilin-eosin
and with Trichrom Masson, immunohistochemically CD 34, CD 117, CD20, CD8 and bcl-2 were
detected. Capillaries, CD 117, CD3, CD20, CD8 cells and fibers were calculated per 1 mm 2 but
adipocytes, were measured by magnification 40x with ruler of Axiostar plus microscope. Bcl-2
expression was evaluated per 100 cells. All data was analyzed by SPSS 17.0, Excel programs. Results:
Women: Men ratio was 1, 6: 1. Mean age for both genders was 48.1 years old. In group of MetSy
common histological pattern were: hyperceratosis, granulosis, dermal fibrosis and a subtle infiltrate
around blood vessel composed of T lymphocytes. Acanthosis, or thickening of the stratum spin-
osum, is typically mild in patients with MetSy. Immunoreactivity for bcl-2 protein has patchy pat-
tern in basal cells with average amount of 39, 1 per 100 basal cells in MetSy and 6, 4 in persons
without it. Conclusions: Decreased epidermal vascularization, because of thickness of blood ves-
sels in dermis may lead to premature skin aging manifestations or at least may impact the prolifer-
ation of keratinocytes. The mononuclear infiltration around blood vessels shows us the inflamma-
tory component of metabolic syndrome which can be cause by oxidative stress.
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Recurrent cellulitis in outpatient primary care: assessing the nature of the problem
L Strazzula and D Kroshinsky Massachusetts General Hospital, Boston, MA
Cellulitis is a significant problem in outpatient medicine and recurrent disease represents a grow-
ing challenge. In efforts to better quantify and qualify the population affected by recurrent celluli-
tis, we conducted a retrospective chart review from 2008-2011 of adult patients diagnosed with cel-
lulitis at least twice in a given year at five outpatient primary care clinics or the Emergency Department
(ED) at Massachusetts General Hospital. Patients who presented to the ED and were subsequently
admitted were excluded. Over 1,000 medical records were reviewed yielding 140 patients meet-
ing criteria for recurrent cellulitis and representing a total of 342 outpatient diagnoses. There were
59 (42.1%) women and 81 (57.9%) men with a mean age of 61.0 years. Patients had a mean of 2.3
diagnoses per year with as many as five diagnoses observed in three patients. 100% of patients
received oral or intravenous antibiotics for each cellulitis diagnosis. The most common risk factors
associated with recurrent cellulitis diagnosis were a history of inflammatory skin disease (42.9%),
chronic lymphedema (35.0%), a history of trauma (35.0%), and diabetes (22.9%). An objective
marker of infection such as fever >100.5 F was only present in 1.9% of cases, whereas leukocyto-
sis was present in 19.5% of diagnoses. 17 patients (12.1%) had significant adverse events related
to antibiotic usage such as drug rash, drug-induced vasculitis, and Clostridium difficile infection.
Cellulitis is a considerable problem in medicine, with many patients having multiple bouts in the
outpatient primary care setting alone. This study attempts to quantify the nature of the problem at
one large medical center to guide future studies. Given the high prevalence of chronic skin disease
and lymphedema in this population, we believe that a substantial proportion of these patients may
have had pseudocellulitis rather than a true infection. A collaborative effort between primary care
physicians and dermatologists may help identify potential mimicking conditions and modify con-
tributing risk factors to reduce the burden of disease.
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